Protocol: I4D-MC-JTJN(b)
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent 
Ovarian Cancer
[STUDY_ID_REMOVED]   
Approval Date: 17-Sep-2018
I4D-MC-JTJN (b)ClinicalProtocol Page 1
LY2606368Protocol I4D-MC-JTJN (b)
APhase 2Study ofPrexasertib inPlatinum -Resistant or
Refractory Recurrent Ovarian Cancer
Confidential Information
The information contained in this protocol is confidential and is intended for the use of clinical investigators.  It 
is the property of Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_882126] (LY2606368 ), unless such persons are bound 
by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. 
Note to Regulatory Authorities :  This document may contain protected personal data and/or commerci ally 
confidential information exempt from public disclosure.  Eli Lilly and Company requests consultation 
regarding release/redaction prior to any public release.  In the [LOCATION_002], this document is subject to 
Freedom of Information Act (FOIA) Exemptio n 4 and may not be reproduced or otherwise disseminated 
without the written approval of Eli Lilly and Company or its subsidiaries.
Prexasertib (LY2606368 )
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_11007] : 20 November 2017
Amendm ent (a) Electronically Signed and Approved by [CONTACT_11007] :  28 June 2018
Amendm ent (b) Electronically Signed and Approved by [CONTACT_57968].
Approval Date: 17-Sep-2018 GMT
I4D-MC-JTJN (b)ClinicalProtocol Page 2
LY2606368Table of Contents
Section Page
Protocol  I4D-MC-JTJN(a) A Phase 2Study ofPrexasertib inPlatinum -
Resistant orRefractory Recurrent Ovarian Cancer ............................................................... 1
Table of Contents ........................................................................................................................ 2
1. Synopsis ............................................................................................................................. 8
2. Schedule of Study  Activities............................................................................................. 10
3. Introduction ...................................................................................................................... 17
3.1. Study  Rationale ............................................................................................................ 17
3.2. Background .................................................................................................................. 18
3.2.1. Descript ion of CHK1 and Prexasertib ................................................................... 18
3.2.2. Rationale for Prexasert ib in Ovarian Cancer ......................................................... 18
[IP_ADDRESS]. Role in DNA -Damage Repair and Replicat ion Stress ...................................... 18
[IP_ADDRESS]. Nonclinical Data ............................................................................................. 19
[IP_ADDRESS]. Clinical Data in Patients with High -Grade Serous 
Ovarian Cancer ............................................................................................... 19
[IP_ADDRESS]. Rationale for JTJN Cohorts ............................................................................. 21
3.3. Benefit/Risk Assessment .............................................................................................. [ADDRESS_1233644] ions.................................................................................................... 30
6.4. Screen Failures ............................................................................................................. 30
7. Treatments ........................................................................................................................ 31
7.1. Treatment s Administered ............................................................................................. 31
7.1.1. Packaging and Labelling ...................................................................................... 31
7.2. Method of Treatment Assignment ................................................................................ 31
7.2.1. Selection and Timing o f Doses ............................................................................. 31
7.3. Blinding ....................................................................................................................... 31
I4D-MC-JTJN (b)ClinicalProtocol Page 3
LY26063687.4. Dose Modificat ion........................................................................................................ 32
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... [ADDRESS_1233645] ions............................................... 41
9.2.3. Com plaint Handling ............................................................................................. 42
9.3. Treatment of Overdose .................................................................................................42
9.4. Safety........................................................................................................................... 42
9.4.1. Safety Measures and Monitoring .......................................................................... 42
[IP_ADDRESS]. Speci al Hepat ic Safet y Data Collect ion and Monitoring 
Criteria ........................................................................................................... 42
9.5. Pharmacokinet ics......................................................................................................... 43
9.6. Pharmacodynamics ...................................................................................................... 43
9.7. Pharmacogeno mics ...................................................................................................... 43
9.8. Biomarkers ................................................................................................................... 44
9.8.1. Tissue Samples for Bio marker Research ............................................................... 44
9.8.2. Other Samples for Bio marker Research ................................................................ 46
9.9. Heal th Economics ........................................................................................................ 46
9.10. Health Outcom e Measures ............................................................................................ 46
10. Statistical Considerations .................................................................................................. 48
10.1. Sample Si ze Determinat ion.......................................................................................... 48
10.2. Popul ations for Analyses .............................................................................................. 49
10.3. Statistical Analyses ...................................................................................................... 49
10.3.1. Efficacy Analyses ................................................................................................ 50
10.3.2. Safety Analyses .................................................................................................... 50
10.3.3. Other Analyses ..................................................................................................... 51
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 51
I4D-MC-JTJN (b)ClinicalProtocol Page 4
LY260636810.3.3.2. Patient Characteri stics.................................................................................... 51
[IP_ADDRESS]. Treatment Compliance .................................................................................... 51
[IP_ADDRESS]. Extent of Exposure ......................................................................................... 51
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 51
[IP_ADDRESS]. Post-Study -Treatment Therapy ....................................................................... 51
[IP_ADDRESS]. Pharmacokinet ic/Bio marker Analyses ............................................................. 52
[IP_ADDRESS]. Biomarker Analyses ....................................................................................... 52
[IP_ADDRESS]. Health Outcom e/Pat ient-Reported Outcomes .................................................. 52
[IP_ADDRESS]. Healthcare Resource Utilization ...................................................................... 53
10.3.4. Interim Analyses .................................................................................................. 53
11. References ........................................................................................................................ 55
I4D-MC-JTJN (b)ClinicalProtocol Page [ADDRESS_1233646] ives and Endpo ints....................................................................... 23
Table JTJN.6. Hem atologic Parameters Requi red Pri or to Each Dose ............................ 32
Table JTJN.7. Dose Adjustments and Delays ................................................................ 33
Table JTJN.8. Prexasert ib Dose Reductions .................................................................. 34
Table JTJN.9. Instrum ents Used to Assess Pat ient-Reported Outcomes ......................... 47
Table JTJN.10. Observed ORR and 60% Credible Interval .............................................. 49
I4D-MC-JTJN (b)ClinicalProtocol Page [ADDRESS_1233647] atinum -
sensit ive, -resistant, or -refractory disease treated with prexasertib. ......... 21
Figure JTJN.7.1. Continued access diagram. ...................................................................... 36
I4D-MC-JTJN (b)ClinicalProtocol Page [ADDRESS_1233648] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 60
Appendix 2. Clinical Laboratory  Tests ........................................................................ 64
Appendix 3. Study  Governance, Regulatory , and Ethi cal Considerati ons.................... 65
Appendix 4. Sampling Schedule for Pharmacoki netics ............................................... 68
Appendix 5. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 69
Appendix 6. Creatinine Clearance Formula .................................................................70
Appendix 7. Protocol  Amendment I4D -MC-JTJN(a) Summary
APhase2Study ofPrexasertib inPlatinum -Resistant orRefractory
Recurrent Ovarian Cancer ....................................................................... 71
I4D-MC-JTJN (b)ClinicalProtocol Page 8
LY26063681.Synopsis
Protocol Title:
A Phase [ADDRESS_1233649] ant or Refractory  Recurrent Ovarian Cancer
Rationale:
Effect ive treatment options for patients with platinum -resistant or pl atinum -refractory  high-grade 
serous ovarian (HGSOC), primary  peritoneal, or fallopi[INVESTIGATOR_882127].  Over 75% of HGSOCs are associated with al terati ons in DNA dam age 
response (DDR) pathways or increased replicat ion stress .  These alterations are predicted to 
increase sensit ivityto a CHK1 inhibitor such as prexasertib. Study  I4D-MC-JTJN (Study JTJN ) 
will evaluate the efficacy  of prexasert ib in both pl atinum -resistant and platinum -refractory  
patients withHGSOC ,primary peritoneal, or fallo pi[INVESTIGATOR_76351].
Objectives and Endpoints:
Objectives Endpoints
Primary
Toestimate theoverall response rate 
(ORR )foreach cohortORR: proportion ofall enrolled patients whoachieve abestoverall
respo nseofPR+CR asdetermined perRECIST version 1.1.
Secondary
Tocharacterize thesafety and
toxicity profile of prexasertibThesafety endpoints evaluated willinclude butarenotlimited tothe
following: AEs, SAEs, clinical laboratory tests, ECGs, vital signs, and
physical examinations
To characterize the PK of 
prexasertibPrexasertib concentrations in plasma
Toestimate secondary efficacy
measures including DCR, DoR, 
CA-125 response, PFS, OSDCR: proportion ofpatients whoachieve abestoverall response of
CR,PRandSD(for at least 4 months) asdetermined perRECIST
version 1.1.
DoR: time from thedate measurement criteria for CRorPR 
(whichever isfirstrecorded) arefirstmetuntil thefirstdate of
documented PD,perRECIST 1.1,orthedate ofdeath from any
cause intheabsence ofdocumented PD.
CA-125 response: atleast a50% reduction in CA-[ADDRESS_1233650] twice the upper limit of the reference 
range and obtained within 2 weeks before starting the treatment , with 
confirmatio n after 4weeks according to GCIG criteria.
PFS: time from enrollment until thefirstradiographic
documentation (asassessed by[CONTACT_36705]) ofprogression
ordeath from anycause intheabsence ofdocumented PD
OS: time from enrollment until death from anycause
Abbreviations:  AEs =adverse events; CR=complete response; DCR =disease controlrate; DoR =duration of
respo nse;ECG =electrocardiogram; GCIG = Gynecologic Cancer Inter group; ORR =overall response rate;
OS=overall survival; PD=pr
ogressive disease; PFS =progr ession -free survival; PK=pharmacokinetics;
PR=partial response; RECIST =Response Evaluation Criteria InSolid Tumors v ersion 1.1 (Eisenhauer et al. 
2009); SAEs =serious adverse events; SD=stable disease.
I4D-MC-JTJN (b)ClinicalProtocol Page 9
LY2606368Overall Design:
Study  JTJN is a multicenter, nonrandomized, parallel cohort,Phase 2 study in patients with
high-grade serous ovarian, primary peritoneal, or fallopi[INVESTIGATOR_76351].
Patients will  be assigned to the following cohorts:
Cohort 1: Platinum -resistant, BRCA negat ive, and received ≥3 lines of priortherapy
Cohort 2: Platinum -resistant, BRCA negat ive, and received <3 lines of prior therapy
Cohort 3: Platinum -resistant, BRCA positive, there is no restrict ion on number of lines of 
prior therapy , but patients must have received prior poly (ADP -ribose) polymerase 
(PARP )inhibitor
Cohort 4:  Platinum -refractory ,BRCA positive or negative, no restri ction on number of 
lines o f prior therapy
Patients wi th BRCA test results posit ive for deleterious or suspected del eterious mutationsare 
referred to as BRCA posit ive,and pat ients with BRCA test results negative for deleterious or 
suspected deleterious BRCA mutations a re ref erred to as BRCA negat ive.  Patients with variants 
of unknown significance should be considered BRCA negat ive.
Number of Patients :
The total sample size is est imated to be approximately  up to 180patients.
Treatment Arms and Duration :
Patients in allcohorts will receive 105 mg/m 2prexasertib as an approximately 60 (+10) minute 
intravenous (IV) infusio n on Day  1and 15 of a 28-day cycle.   Patients will be treated until 
radiographically  docum ented di sease progressi on, unacceptable toxicit y, or another permitted 
reason for study  discont inuat ion.
I4D-MC-JTJN (b)ClinicalProtocol Page 10
LY26063682.Schedule of Study Activities
I4D-MC-JTJN (b)ClinicalProtocol Page 11
LY2606368Table JTJN. 1. Schedule of Inclusion and Baseline Assessments
Study Period Baseline
Cycle Baseline (Screening)
Visit 0
Duration Up to 42 days
Relative Day C1D1 ≤42 ≤28 ≤14
Procedure 
Category Procedure Comments
Study Entry/
EnrollmentInformed Consent 
Form signedX Prior to conducting any protocol specific tests/procedures .
Cohorts 1 -3: 
Confirm availability
oflocal BRCA resultXData from a blood or tissue based test areacceptable (i.e.,either germline 
or somatic tests are acceptable) . The test may have occurred prior to 
consent. If both somatic and germline status are known, the somatic 
status should be used for cohort assign ment. Patients in Cohort [ADDRESS_1233651] local BRCA results.
Inclusion/Exclusion 
evaluationXAll criteria except theconfirmation of availability of local BRCA test
results mustbe assessed within [ADDRESS_1233652] dose .
Medical HistoryInitial history/
preexisting 
conditionsX Including significant historical illnesses that resolved .
Habits X Only smoking history .
Physical 
ExaminationPhysical 
examinationX Includes height and weight .
ECOG performance 
statusX
Vital signs X Temperatu re, blood pressure, pulse rate .
Tumor 
AssessmentRadiologic imaging 
according to 
RECIST version 1.1
and tumor 
measurement 
(palpable or visible)XBaseline radiological tumor assessment per RECIST version 1.1. 
Radiologic assessments obtained previously as part of routine clinical 
care may be used as baseline assessment provided they were done no 
more than [ADDRESS_1233653] dose of study drug.
Adverse Events Collection/ CTCAE 
GradingX CTCAE version 4.0 .
Concomitant Medication Notation X Includes information on over -the-counter and prescription analgesics 
Laboratory/
Diagnostic TestsHematology X See Appendix [ADDRESS_1233654] prior 
to biopsy (to confirm eligibility ) and a negative pregnancy test within [ADDRESS_1233655] is acceptable .
ECG X Single local ECG .
Pretreatment biopsy XMay be performed at any time, but sample should be taken only after 
study eligibility is confirmed .
I4D-MC-JTJN (b)ClinicalProtocol Page 12
LY2606368Schedule of Inclusion and Baseline Assessments
Study Period Baseline
Cycle Baseline (Screening)
Visit 0
Duration Up to 42 days
Relative Day C1D1 ≤42 ≤28 ≤[ADDRESS_1233656] pain will be 
administered by [CONTACT_882148].
NFOSI -18 XNFOSI -18 will be administered by [CONTACT_882149].
Abbreviations:  C1D1 = Cycle 1 Day 1; CTCAE = Common Terminology Criteria for Advers e Events; 
ECG =electrocardiogram; ECOG = Eastern Cooperative Oncology Gro up; EOI = end of infusion; 
IV=intravenous; NRS = numeric rating scale ; NFOSI -18 = National Comprehensive Cancer N etwork –
Functional Assessment of Cancer T herapy –Ovarian Symptom I ndex -18; RECIST = Response Evaluation 
Criteria in Solid T umorsversion 1.1 ( Eisenhauer et al. 2009 ).
I4D-MC-JTJN (b)Clinic al Protocol Page 13
LY2606368Table JTJN. 2. On-Study Treatment Schedule of A ctivities
Study Period Cycle
Cycle/Visit 1 2-n
Duration 28days 28days
Relative Day within Dosing Cycle 1 15 1 15
Procedure 
Category Procedure Notes
Physical
ExaminationPhysical e xamination X XIncludes weight and calculated BSA.  May be completed up to 7 day s prior to treatment 
infusion.
Vital signs X X X XIncludes blood pressure, pulse, and temperature.  Complete before each treatment 
infusion.
ECOG performance status X X Complete before treatment infusion onDay 1 .
Laboratory/ 
Diagnostic 
TestsHematology X X X XMay be drawn up to [ADDRESS_1233657] X XApplies only to women of childbearing potential.  Where required by [CONTACT_1769]/ regulation 
or institutional guidelines, perform once every 28 days (±7 days). Either a urine or serum 
test is acceptable .
CA-125 X X May be drawn up to 3 days before the day of dosing
PK sampling X XSparse PK sampling will be conducted over multiple cycles of therapy (see Appendix 4
for additional details).
Stored blood sample for 
pharmacogeneticsX Collect once.  Sample can be collected at any time if not collected on Day [ADDRESS_1233658] only in Cycles 1 and 4.  May be drawn up to 3 days before the day of dosing.
ECG X X X XSingle local ECG collected at each time point only. Cycle 1 Day 1 and Cycle 2 Day 1:  
predose, within 15 mi n after EOI.   Cycle 1 Day 15, C ycle 2 Day 15, and Cycle 3 -n: Day 1 
and 15 prior to each dose. Additional ECGs may be obtained at the discretion of the 
investigator.  When ECGs and PK are required at the same time point, the ECG should be 
obtained prior to the PK draw .
Optional tumor b iopsy XCan occur at any time during patient's treatment . Patients should have adequate 
neutrophils and platelets prior to biopsy. See Section 9.8.1 .
I4D-MC-JTJN (b)Clinic al Protocol Page 14
LY2606368On-Study -Treatment Schedule of Activities
Study Period Cycle
Cycle/Visit [ADDRESS_1233659] version 1.1and 
tumor measurement 
(palpable or visible)XPerform approximately every 8 weeks (±1 week) up to 1 year, thereafter every 12 weeks 
(±1 week). The first scan should be approximately 8 weeks ( ±1 week ) from Cycle 1
Day1.The 8-week /12-week scanning interval should be maintained even if cycles are 
delayed.  As a result, the scans may not always occur at the end of a cycle.  The same 
method of imaging used at baseline should be used for each subsequent assessment.  
Scans should also be obtained as clinically indicated .  Scans to confirm responses may be 
performed sooner than [ADDRESS_1233660] 4 weeks following th e initial 
observation of an objective response.  The next scan should be 8 weeks (±1 week ) 
following the confirmatory scan.
Adverse Events Collection/ CTCAE GradingXCollect throughout thestudy, CTCAE v ersion 4.0 ;includes hospi[INVESTIGATOR_602], emergency 
department visits, and/or occurrence of SBO .
Concomitant Medication NotationXCollect throughout thestudy; includes transfusions (platelets and RBC) andinformation 
on over -the-counter and prescription analgesics use .
Health 
Outcome 
AssessmentsWorst Pain NRS XThe patient will complete the single item worst pain NRS, at home immediately prior to 
bedtime every day .  Collection of the Worst P ain NRS wil l be discontinued during study 
treatment at progression o r Day [ADDRESS_1233661] .
NFOSI -18 XThe NFOSI -18 will be administered by [CONTACT_882150] D ay 1 of every cycle , beginning with 
Cycle 2.
Study 
TreatmentPrexasertibX X X XAdminister on Day s1 and 15 of every 28 -day cycle, IV over approximately 60 (+10) 
minutes .
Note:  Baseline/screening labs drawn within the indicated window of C1D1 may be used for both screening/baseline and C1D1 labs.  Note that eligibility
(including baseline/screening labs) must be confirmed prior to obtaining the biopsy and patient should fully recover from the acute effects of the biopsy prior 
to starting treatment.
Abbrevia tions:  BSA = body surface area ; CT = computed tomogr aphy ; CTCAE = Common Terminology Criteria for Adverse Events; 
ECG =electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EOI =  end of infusion; IV = intravenous; NRS = nume ric rating scale ; 
NFOSI -18= National Comprehensive Cancer Network –Funct ional As sessment of Cancer T herapy –Ovarian Symptom Index -18, PK = pharmacokinetics; 
QTcF =corrected QT interval using Friderici a’s formula; RBC = red blood cell; RECIST = Response Evaluation Criteria in Solid T umors version 1.1 
(Eisenhauer et al. 2009 );SBO = small bowel obstruction .
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233662]-Discontinuation Follow -Up
Short-Term Follow -UpaLong -Term Follow -Upb
Duration 30 ±5 days 60 ± 14 days
Visit 801 802-X
Procedure 
Category Procedure Comments
Physical 
ExaminationPhysical examination (including weight) X
Vital signs X Includes blood pressure, pulse, and temperature .
ECOG performance status X
Tumor 
AssessmentRadiologic imaging according to 
RECIST version 1.1X XPerform approximately every 8 weeks (±1 week ) up to 1 year, 
thereafter every 12 weeks ( ±1 week ) by [CONTACT_882151], until the patient has documented 
disease progression, starts another therapy, or study completion. 
The same method of imaging used at baseline should be used for 
each subsequent assessment.  Scans should also be obtained as 
clinically indicated.
Tumor measurement (palpable or visible) X
Adverse Events Collection/ CTCAE Grading X XCTCAE v ersion 4.0 ; for visit 801: includes hospi[INVESTIGATOR_602], 
emergency department visits, and/or occurrence of SBO .After Visit 
801, only study treatment -related serious events are to be reported.
Concomitant Medication Notation XIncludes transfusions (platelets and RBCs) and information on over -
the-counter and prescription analgesics use.
Laboratory /
Diagnostic TestsHematology X See Appendix [ADDRESS_1233663] approximately every 8 weeks (±1week ) up to 1 year, 
thereafter every 12 weeks ( ±1 week ) at same time as radiologic 
imaging (+/ -3 days) , until the patient has documented disease 
progression, starts another therapy, or study completion.
ECG X
Plasma biomarker sample X
Optional post -treatment biopsy X Can be obtained any time prior to the start of next therapy
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233664]-Discontinuation Follow -Up
Short-Term Follow -UpaLong -Term Follow -Upb
Duration 30 ±5 days 60 ± [ADDRESS_1233665] Pain NRS , NFOSI -18 XPRO instrumentation will be administered during the short term 
follow -up visit prior to extensive interaction with site staff.
Follow -Up Survival a ssessment XApproximately every 9 0 (±14) days (telephone assessment is 
acceptable)
Abbreviations:  CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse E vents; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology 
Group; NRS = numeric rating scale ; NFOSI -18 = National Comprehensive Cancer Network –Functional Assessment of Cancer T herapy –Ovarian Symptom Index -18; NRS = 
numeric rating scale ;PRO = patient -reported ou tcome; RECIST = Response Evaluation Criteria in Solid T umors version 1.1 (Eisenhauer et al. 2009) ; SBO =small bowel 
obstruction .
aPeriod begins the day after the decision that the patient will discontinue study treatment is made and lasts approximately [ADDRESS_1233666] to follow -up.
Table JTJN. 4. Continued A ccess Schedule of A ctivities
Study Treatment Follow -Upa
Visit 501-5XX 901
Comments Procedureb
Adverse event collection X X
Administer prexasertib X IV over approximately 60 (+10) minutes once every 14 days.
Abbreviations:  IV = intravenously .
aContinued access follow -up begins 1 day  after the patient and the investigator agree that the patient will no longer continue treatment in the contin ued access 
period and lasts approximately 30 days. No follow -up proc edures will be performed for a patient who withdraws informed consent unless he or she has 
explicitly  provided permission and consent.
bEfficacy assessments will be done at the investigator’s discretion based on the standard of care.
I4D-MC-JTJN (b)Clinic al Protocol Page 17
LY26063683.Introduction
3.1. Study Rationale
Ovarian cancer is the fift h leading cause of cancer deaths for women in the [LOCATION_002] (Siegel 
et al. 2017 ).  Approximately 80 -85% of  all carcinomas are serous tumors, the vast majorit y being 
high-grade serous ovarian cancer (HGSOC) (Soslow 2008) . High -grade serous adenocarcinomas 
from the fallopi[INVESTIGATOR_882128] Müllerian
epi[INVESTIGATOR_882129].  As a resul t, the yare commo nly 
included in ovarian cancer clinical trials (Dubeau and Drapkin 2013).   Frontline chemotherapy 
consists of a platinum and taxane doublet with or without bevacizumab (Ozols et al. 2003; Vasey 
et al. 2004; Katsumata et al. 2009; Burger et al. 2011; Perren et al. 2011) .  Although HGSOC s
are init ially chemo -sensi tive, up to 80% of pat ients relapse leading to a disappo inting 46.2% 
overall survivorship at 5 y ears fro m ovari an cancer diagnosis (Ozols et al. 2003; Rust in et al. 
2010; SEER [WWW]) .  Therapy  at the t ime of recurrence is determined largely by [CONTACT_941] t ime 
elapsed since com pleting initial plat inum -based chemotherapy; patients with 
“platinum -sensi tive” and “plat inum -resistant” relapse have disease progressing >6 months or 
<6months from the previous plat inum -based treatment, respectively (Gore et al. 1990; Hoskins 
et al. 1991; Davis et al. 2014) .Patients with plat inum -refractory  disease progress during or 
within 4weeks of the l ast dose of the ini tial line of platinum -based chem otherapy  for ovarian 
cancer . The standard of care for a woman wit h a plat inum -sensit ive recurrence is retreatment 
with a platinum doublet ( Parm ar et al . 2003).
Unlike platinum -sensit ive disease, there is not a clear standard of care for platinum -resistant or 
platinum -refractory disease, and the agents used vary by [CONTACT_882152] .  Avariet y of 
single -agent chemotherapi[INVESTIGATOR_882130] -resistant disease, including PEGylated
liposomal doxorubicin (PLD), gemcitabine, paclitaxel, topotecan, docetaxel, and etoposide 
(National Comprehensive Cancer Network [ NCCN ][WWW]) . However, patients wi ll ultimately 
relapse and new agents areneeded for platinum -resistant patients who have failed or exhausted
standard treatment options.
Poly (ADP -ribose) polymerase (PARP) inhibitors such asolapari bandrucaparib have been 
approved asmonotherapy for patients withrecurrent ovarian cancer, especially for patients with
germline BRCA1 or BRCA2 mutations(Alsop et al. 2012; Pennington et al. 2014; NCCN 
[WWW]) . Notably, a pooled subgroup analysis of the rucaparib studies ARIEL2 and Study 10 
showed that in HGSOC patients who had received ≥2prior therapi[INVESTIGATOR_014], rucaparib monotherapy had 
a higher overall re sponse rate (95% confidence interval [CI] ) in p latinum -sensit ive patients 
(65.8% [54.3 -76.1] )compared with platinum -resistant (25.0% [8.7 -49.1] )or platinum -
refractory  patients (0% [0.0 -41.0]) (Oza et al. 2017 ).
I4D-MC-JTJN (b)Clinic al Protocol Page 18
LY26063683.2. Background
3.2.1. Description of CHK1 and Prexasertib
Checkpo int kinase 1 ( CHK1 )is amultifunctional protei nkinase and regul ator oftheDNA 
damageresponse (Dai and Grant 2010). Inresponse to exogenous DNA damage, CHK1
mediates cell-cyclearrest to allow time for DNA repair orifthedamage is extensive, to trigger
apoptosis. CHK1 is essential forhomologous recombination repair (HRR) ofdouble -strand
DNA breaks. Italsoaffects theinitiationofDNA replication originfiring,stabilizat ionof
replication forks, resolution ofreplication stress, andcoordination ofmitosis, even in the
absence ofexogenous DNA damage (McNeely etal.2014).   Thus, the inhibit ion ofCHK1
disrupts DNA replicat ion, induces DNA damage, andsubsequent lyprevents repair, leading 
eventually to death by [CONTACT_882153] (King etal.2015).  CHK1 inhibit ionalsoenhances theactivit yofDNA -damaging
cytotoxi cchemotherapeutics by[CONTACT_882154]-cycle control andDNA repair (McNeely et
al. 2014). Tumors thathave high levels ofreplicati on stress and/or defects in DNA damage
repair pathways such asHGSOC are hypothesized to besuscept ibleto the effects ofaCHK1 
inhibitor (Lin etal.2017; Murai 2017).
Prexasertib is an inhibitor of CHK1 which has been evaluated as a treatment for patients with 
advanced cancers and may have utilit y both as monotherapy and in combination with other 
DNA -damaging agents, targeted agents, or radiation (Zeng et a l. 2017) .
3.2.2. Rationale for Prexasertib in Ovarian Cancer
[IP_ADDRESS]. Role in DNA -Damage Repair and Replication Stress
Preclinical data suggest that tumors with high endogenous levels o f replicat ion stress are m ore
sensit ive to single -agent CHK1 inhibitors (Cole et al. 2011; Brooks et al. 2013; Lecona and
Fernández -Capetillo 2014). CCNE1 (cyclin E1) i samplified in 15- 20% of  HGSOCs
(Etem admoghadam et al. 2013; Konstant inopoulos et al. 2015), and overexpressio n of cyclin E
induces replicat ion stress and DNA damage that activates HRR (Jones et al. 2013). CHK1
inhibit ion by[CONTACT_882155]1 -amplified ovarian cancers maydiminish the abilit yof cells
to tol erate high l evels o freplicati on stress induced by[CONTACT_4721] E overexpressio n by[CONTACT_882156]1 -mediated replicat ion fork stabilization and repair of collapsed forks through HRR as well
as exacerbat ingreplicat ion stress by[CONTACT_882157].
Defect ive DNA repai ralso resul ts in increased sensit ivityto single -agent CHK1 inhibitors
(Rundle et al. 2017).  Approximately half o f HGSOCs harbor mutations in genes that modulate
HRR (Konstantinopoulos et al. 2015; Lord and Ashworth 2016). Germline BRCA1 and BRCA2
mutati ons ar e present in about 15% of epi[INVESTIGATOR_882131] 22.6% of
HGSOCs, and so matic BRCA1 and BRCA2 mutations have been ident ified in about 7% of 
high-grade serous epi[INVESTIGATOR_261263] (Konstantinopoulos et al. 2015).  Furthermore,
epi[INVESTIGATOR_882132]1 andRAD51C has b een observed in 10 -20% and 3%of 
HGSOCs, respectively (Konstant inopoulos et al. 2015; Lord and Ashworth 2016). HRR 
deficiency through inact ivation of RAD51 confers hypersensit ivitytoCHK1 inhibit ion 
I4D-MC-JTJN (b)Clinic al Protocol Page 19
LY2606368(Krajewsk a et al . 2015); therefore, defects in HRR may confer an increased sensit ivityto 
doubl e-strand DNA breaks induced by[CONTACT_882158]. Alterations in other DNA damage response 
andrepair pathways may similarly contribute to CHK1 inhibitor sensit ivityin ovarian cancer 
(Murai 2017) and include mutations in ATM or ATR observed in 2% ofHGSOCs and mutations 
in genes of the Fanconi anemia DNA repai r pathway observed in 5% of HGSOCs (Lord and 
Ashworth 2016).
The potential for synthet ic let halitybetween HRR deficiencies orother DNA repai r defects and
prexasertib as well as the role of CCNE1 in increasing replicat ion stress make CHK1 an
attractive target in this disease.
[IP_ADDRESS]. Nonclinical Data
Broad anti proliferat ive effects of prexasertib monotherapy  were demonstrated in various t issue 
culture studi es using growth inhibit ion or cl onogenic survival in so ft agar as a phenotypic 
endpo int.  Apanel of 621genomically  characteri zed tum orcell lines derived fro m mult iple 
cancer ty pes and vari ous histol ogieswere tested .  Prexasert ibshowed wi despread 
antiproliferat ive effects ;growth of 66% of these lines was inhibited at half-maximal inhibitory  
concentration (IC50)concentrations of ≤50nM .  Further , the antiproliferat ive act ivity of 
prexasertib in the subset of 23 cell lines derived from human ovarian cancers showed IC 50values 
that ranged between 2 and 320 nM; 70% (16 of 23) of these lines had IC 50values ≤50 nM.
Studi es in xenograft tumors also demonstrated prexa sertib tobe a potent inhibitor of tumor cell 
growth .  Studies in the orthotopi[INVESTIGATOR_882133] -3 model using a 3-days-
on/4-days
-off schedule showed prexasertib monotherapy resulted in a dose -dependent inhibit ion 
of tumor growth .  At the end of the dosing period (Day 31), in hibition was52.7% and 70.7% for 
groups treated with 4 and 12 mg/kg of prexasert ib, respectively , com pared wi th vehicle .  
Necropsy  showed dose -dependent reductions in ascites fluid vo lume and number of tumor 
colonies (l ocalized metastases) in the peritoneal cavit y.  The seresul ts are concordant with 
studi es ofsubcutaneous -implanted xenograft such as the A -[ADDRESS_1233667] ive dosing period was60.3%, 63.1%, and 93% after monotherapy  
with 1, 4, and 12 mg/kg of prexasertib, respectively (McNeely et al . 2011) .
[IP_ADDRESS]. Clinical Data in Patients with High -Grade Serous Ovarian Cancer
The safet y profile of prexasertib is consistent wi th toxicities co mmo nly observed wi th standard 
of care cy totoxi c agents used to treat cancer .  Hematologic toxicit y is the most frequent and 
severe toxicit y after treatm ent wi th 105 mg/m2prexasertib every  [ADDRESS_1233668] also been observed, but can be 
mitigated by  [CONTACT_882159] ( G-CSF)
andtransfusio ns.Events with a fatal outcome have occurred fo llowing sepsis/infect ion and 
clinically significant bleeding.  Patients should be closely  monitored f or signs of  infect ions, 
sepsis, and bleeding co mplications.  Clinical data f rom com pleted and ongoing studies across the 
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233669] igator’s Brochure ( IB).  Interim data available fro m 
1study  in pat ients with ovari an cancer are summarized below .
The National Cancer Inst itute (NCI; principal investigator ,Jung-min Lee, MD) i s sponsoring a 
Phase 2 pi[INVESTIGATOR_48505] a primary  objective of determining the overall response rate (ORR )of 
prexasertib monotherapy  in pat ients with breast cancer , ovari an cancer, or prostate cancer 
([STUDY_ID_REMOVED]
, I4D -MC-E001[E001] ).  Patients receive prexasertib on Days 1 and 15 of a 
28-day cycle at the recommended Phase 2 dose ( RP2D )of 105 m g/m2(NCI 2017b).   Preliminary 
resul ts from 32heavily pretreated female pat ients with HGSOC were presented at the meet ing of 
the European Societ y for Medical Onco logy (ESMO) in October 2016 (Lee et al. 2016).  Interim 
data included 7 patients in Group 1 ( with docum ented del eterious germline BRCA1 /BRCA 2
mutati on [g BRCA1/2 m])and 25 patients in Group 2 (with negat ive family history  of heredi tary
breast ovari an cancer syndrome or negative g BRCA1/[ADDRESS_1233670]) (Lee et al. 2016) .
Grade 4 neutropenia was observed in 69% of pat ients and 75% of  the Grade 3 and 4 neutropenia 
events resolved to Grade ≤2 within 8 days after onset ; 2patients (6%) had febrile neutropenia
and 56% received G- CSF.  Other toxi cities included decreased white blood cell (WBC) count
(78%), anemia (66%), and decreased platelet count (34%).  Nonhematologic adverse events 
(AEs)included fat igue, nausea, vo miting, and diarrhea (9% each) ; all were generally  mild (Lee 
et al. 2016) .  One patient hadGrade 3 diarrhea and vom iting during infusion .  Only 1 pat ient 
(3%) required a dose reduction (80 mg/m2) (Lee et al. 2016) .
Figure JTJN. 3.1presents a plot of best responses for target lesio ns by [CONTACT_882160].  Of the 25 patients treated in Group 2, 20 were evaluable for tumor 
response.  Seven (35%) evaluable pat ients achieved partial response (PR)(including [ADDRESS_1233671] atinum -sensi tive and 5 whose disease was plat inum -resistant or -refractory).  The 
median duration of response was 6 months (range:  2 -13 m onths), and 5 (25%) patients a chieved 
stable disease ( SD)lasting ≥4 months, for a DCR of 60%.  Patients were heavily pretreated.  
Platinum -resistant pati ents had a median of 4 prior lines of therapy  (range : 1-13).  Of the 7 
patients treated in Group 1, 6 were evaluated for tumor response.  None of the evaluable pat ients 
in Group 1 achieved CR or PR, but 4 (67%) achieved SD lasting ≥
4months, for a DCR of 67%.  
As wi th Cohort 2, pati ents ha d received numerous prior tr eatments ( median :  7, range : 3-12).  
These preliminary results suggest that prexasert ib could be a novel approach to improve the
outcom es of  patients wi th HGSOC (Lee et al. 2016) . 
I4D-MC-JTJN (b)Clinic al Protocol Page 21
LY2606368Abbreviations:  gBRCA m = germline BRCA mutated; HGSOC = high -grade serous 
ovarian cancer. Whitebar=platinum -sensitive disease ; black bar =platinum -resistant 
or –refracto rydisease .
Figure JTJN. 3.[ADDRESS_1233672] response for target lesions, among pati ents with platinum -
sensitive, -resistant , or -refractory disease treated with prexasertib.
[IP_ADDRESS]. Rationale for JTJNCohort s
Patients enrolled in Study  JTJN will be assigned to one of 4 cohorts :
Cohort 1: Platinum -resistant, BRCA negat ive, and received ≥3 lines of prior therapy
Cohort 2: Platinum -resistant, BRCA negat ive, and received <3 lines of prior therapy
Cohort 3: Platinum -resistant, BRCA positive,there is no restri ctions on number of lines 
of prior therapy , but patients must have received prior PARP inhibitor
Cohort 4: Platinum -refractory ,BRCA positive or negative, no restri ctions on number of 
lines o f prior therapy .
Patients wi th BRCA test res ults posi tive for deleterious or suspected del eterious m utations are 
referred to as BRCA posit ive, and pat ients with BRCA test results negative for deleterious or 
suspected deleterious BRCA mutations are referred to as BRCA negat ive.  Patients with variants 
of unknown significance should be considered BRCA negat ive.
As described in Section [IP_ADDRESS] , preliminary data f rom Study E001 suggest clinical benefit of 
prexasertib in heavily pretreated patients ( Lee et al. 2016 ).  To test this hypothesis, Cohort [ADDRESS_1233673] , such as BRCA mutations, are reported to be mutually exclusive with CCNE1
amplificat ion (Kroeger and Drapkin 2017 ).  As described in Sect ion3.2.2.1 , CCNE 1
amplificat ion may increase replicat ionstress and resul t in sensit ivity to a CHK1 inhibitor such as 
prexasertib .  Notably , in Study  E001 all pat ients wit h BRCA mutation had been treated with a 
PARP inhibitor (Lee et al. 2016 ). Mechanisms of PARP inhibitor resistance that restore HRR 
may lead to diminished sensi tivityto prexasert ib;priortreatment with PARP inhibitors could-80-60-40-20020406080100120Change from baseline 
in sum of longest diameters (%)HGSOC gBRCAm
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233674] been characterized (Lord and 
Ashworth 2013 ;Rondinelli et al. 2017), s ome of which woul d not be implicated in cross -
resistance to prexasertib.   
Cohort [ADDRESS_1233675] s of 
prexasertib in pat ientswith a BRCA mutation who hada prior PARP inhibitor . Study E001 
enrolled a cohort of 7 patients with the germline BRCA mutation, of  which 6 patients had 
platinum -resistant or –refractory  disease (Lee et al . 2016) .  Cohort 4in Study  JTJN will include 
platinum -refractory  patients to determine anyprexasertib benefit in these high -unmet m edical 
need pat ients.
Asdescribed in Section 3.1, gemci tabine, pacli taxel , and PLD are commo nstandard of care 
agents for HGSOC recurrent disease. The present study , JTJN, coul d prom pt the ini tiation of  a 
rando mized controlled trial that m ay include investigator's choice of these chemotherapy options 
as the control arm. Excluding patients (Cohorts 1 -3) that have received more than two of these 
agents for plat inum resistant disease is consistent with the entry criteria that are likely to be
applied in future studies.
3.3. Benefit/Risk Assessment
Given the high unmet need for addit ional therapi[INVESTIGATOR_882134] -resistant or –refractory  
HGSOC, the mechanist ic rati onale support inga role for CHK1 inhibit ion to improve outcom es 
for pati ents wi th HGSOC, nonclinical model data (including HGSOC) on prexasert ib 
monotherapy , prexasert ib clinical safet y profile ,and preliminary  efficacy observed in pat ients 
with HGSOC, the ri sk/benefit assessment supports evaluat ion ofprexasertib mo notherapy  in the 
proposed patient populat ion.  More information onknown and expected benefits, risks, serious 
adverse events (SAEs), and reasonably ant icipated AEs of prexasert ibare described in the IB.
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233676] ives and endpo ints ofthe stu dy.
Table JTJN .5. Objectives and Endpoints
Objectives Endpoints
Primary
Toestimate theORR foreach cohort ORR: proportion ofall enrolled patients whoachieve abestoverall
respo nseofPR+CR asdetermined perRECIST version 1.1.
Secondary
Tocharacterize thesafety andtoxicity
profile ofprexasertibThesafety endpoints evaluated willinclude butarenotlimited tothe
following: AEs, SAEs, clinical laboratory tests, ECGs vital signs,
andphysical examinations
To characterize the PK of prexasertib Prexasertib concentrations in plasma
Toestimate secondary efficacy
measures including DCR, DoR, 
CA-125response, PFS, OSDCR: proportion ofpatients whoachieve abestoverall 
respo nseofCR,PRandSD(for at least 4 months) as
determined perRECIST version 1.1.
DoR: time from thedate measurement criteria for CRorPR 
(whichever isfirstrecorded) arefirstmetuntil thefirstdate of
documented PD,perRECIST 1.1criteria, orthedate ofdeath
from anycause intheabsence ofdocumented PD.
CA-125 response: atleast a50% reduction in CA-[ADDRESS_1233677] twice the upper limit of the 
reference range and obtained within 2 weeks before starting the 
treatment , with confirmation after 4weeks according to GCIG 
criteria.
PFS: time from enrollment until thefirstradiographi c
documentation (asassessed by[CONTACT_36705]) of
progr ession ordeath from anycause intheabsence of
documented PD
OS: time from enrollment until death from anycause
Tertiary/Exploratory
To assess the relationship between 
biomarkers, prexasertib exposure 
(PK), and clinical outcomes Biomarker research assessed from blood ortissue samples, unless
precluded by[CONTACT_427]
Plasma concentration of prexasertib
Clinical outcomes data
Toevaluate patient -reported outcom es 
using NCCN -FACT -FOSI [ADDRESS_1233678] P ain NRS Change f rom baseline
Time to progression
Association between time to pain progression and analgesic 
consumption
Association between time to progression and select efficacy 
outcomes
Abbreviations:  AEs =adverse events; CR=complete response; DCR =disease controlrate; DoR =duration of
respo nse;ECG =electrocardiogram; GCIG = Gynecologic Cancer Intergroup ;NFOSI -18 = National Comprehensive 
Cancer N etwork –Functional Assessment of Cancer T herapy –Ovarian Symptom Index -18; NRS = numeric 
rating scale; ORR =overall response rate; OS=overall survival; PD=progr essive disease; PFS =progr ession -free
survival; PK=pharmacokinetics; PR=partial response; RECIST =Response Evaluatio nCriteria InSolid
Tumo rs version 1.1 (Eisenhauer et al. 2009); SAEs =serious adverse events; SD=stable disease.
I4D-MC-JTJN (b)Clinic al Protocol Page 24
LY26063685.Study  Design
5.1. OverallDesign
Study  I4D- MC-JTJN is amulticenter, nonrando mized, parallel cohort, Phase 2 study in
approximately up to 180patients withhigh-grade serous ovarian, primary peritoneal, orfallopi[INVESTIGATOR_882135].   Patients will be assigned to the fo llowing cohorts:
Cohort 1: Platinum -resistant, BRCA negat ive, and received ≥3 lines of prior therapy
Cohort 2: Platinum -resistant, BRCA negat ive, and received <3 lines of prior therapy
Cohort 3: Platinum -resistant, BRCA positive, there is no restrict ion on number of lines o f 
prior therapy , but m ust have received prior PARP inhibitor
Cohort 4: Platinum -refractory ,BRCA positive or negative, no restri ctions on number of 
linesof prior therapy
Interim analyses willoccur atspecified intervals. Based on protocol -defined rules,enrollment to
acohortcan stop due to lack ofefficacy orcontinue ateach interim analys is unt il the total
sample sizeis reached. See Section 10.3.4 for further details regarding interim analyses.
5.2. Number of Patients
Themaximum total sample size of this study is estimated to be approximately 180patients. For 
each of the 4 cohorts, the minimum sample size is approximately 20 patients.  The sample size 
for each cohort will bedependent on the outcomes of the interim analyses. As cohorts are 
halted, new eligible patients will be allocated to th e enrolling cohorts. As a result, the maximum  
sample size of a single cohort is approximately  120pati
ents (e.g.,if enrollment to all but one of 
the cohorts is stopped after the first interim analysis).
5.3. End of Study Defini tion
Study  com pletionoccurs after the clinical trial database is locked and final analysis o f primary  
and secondary  endpoints have been performed. End of the trialis the date of the last visit or last 
scheduled procedure shown in the Schedule of Activit ies (Section 2) for the last patient.
5.4. Scientific Rationale for Study Design
An open -label, parallel cohort , nonrandomized Phase [ADDRESS_1233679] ion 5, and details o f the sam ple size determinat ion are provided in 
Secti on 10.1.
5.5. Justification for Dose
Based on the nonclini cal prexasertib pharmacokineti c (PK)
/pharm acodynamic model (inhibit ion 
of phosphorylated CHK1 andtumor growth response in Calu -6 xenografts )used to predict the 
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233680]-in-human 
dosing ( FHD )study  JTJA dem onstrating that a body surface area ( BSA )-based dose regimen is 
justified for prexasertib administrati on,the similar systemic exposure and similar safet y profile 
between schedules o f administration , as well as the increased pat ient convenience, 105mg/m2of 
prexasertib on Day 1 of a 14 -day sched ulewas selected as the RP2D.
The populat ion PK predicted (from 1 000 simulated individual PK profiles ) median AUC (0-72)
(2034 ng •hr/ml)following administrati on of  105 mg/m2every 14 days isgreater than the median 
AUC (0-72) (1896 ng•hr/mL) predi cted from a Cal u-[ADDRESS_1233681] 72 hours (Cav,72) predicte d from the 
popul ation PK model fro m Study  JTJA after105g/m2(approximately 28 ng/mL ) is greater than 
the IC 50(14.1 ng/mL) determined from the single -agent nonclinical Calu -6xenograft 
PK/pharmacodynamic model, also dem onstrating that the prexasertib systemic exposure at the 
R2PD i sin a potenti allyefficaci ousrange .  Addit ional details aredescribed in Section s5.2.3 and
6 of the IB.
I4D-MC-JTJN (b)Clinic al Protocol Page 26
LY26063686.Study  Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet allof the fo llowing cri teria
[1] Women who have histologically orcytologi cally verified high-grade serous ovarian,
primary peritoneal orfallopi[INVESTIGATOR_882136].
[2] Cohorts 1 to 3:  Have platinum -resistant disease, which is defined asdisease
progression within6months of lastdose ofplatinum-based chemotherapy .  
Progression due to rising CA125 only  is not consi dered as platinum -resistant di sease.
Cohort 4: Have primar y platinum -refractory disease defined asdisease progression
during or within4 weeks after the last dose of initiallineofplatinum -based
chemoth erapy .
Note:  disease progression may be either radiographic progression or documented 
clinical progression.  Residual disease is not considered progression.
[3] Cohort 1 :  Are BRCA negative and h ave received 3 or m oreprior lines of therapy for 
high-grade serous ovarian, primary  peritoneal, or fall opi[INVESTIGATOR_76351] (including 
immunotherapy , targeted therapi[INVESTIGATOR_014], or chemotherapy (systemic or intraperitoneal ).
Cohort 2 :  Are BRCA negative andhave received less than 3 prior lines of therapy for 
high-grade serous ovarian, primary  peritoneal, or fall opi[INVESTIGATOR_76351] (including 
immunotherapy , targeted therapi[INVESTIGATOR_014], or chemotherapy (systemic or intraperitoneal ).
Note for Cohorts 1 and 2:  Each line of therapy  is preceded by  [CONTACT_882161](initial therapy  is considered the first line) .  Switch 
of an agent wi thin the same drug class (for example, cisplat in to carboplatin) within a 
regimen to m anage toxicit y does not define the start of a new line o f therapy .  
Similarly, maintenance therapy  (continuat ion maintenance or switch maintenance) 
will not be considered a new line of treatm ent.  Hormonal therapy is not considered a 
line of therapy .  All  adjuvant therapy  shoul d be considered as a line of therapy . 
Cohort 3:  Are BRCA posit ive and have previously received a PARP inhibitor at any 
time fo llowing di agnosis . Note: there is no restriction on number of lines of prior 
therapy .
Cohort 4: Are BRCA posit ive or negative; no restrict ion on number of lines of prior
therapy . 
[4] H ave a performance status (PS) of 0 or1 on the Eastern Cooperative Onco logyGroup 
(ECOG) scal e (Oken et al. 1982 )
.
[5] H avediscontinued all previous treatments for cancer and recovered from acute 
effects of therapy .  Pati ents m ust be discont inued from  previous treatments, as per
below:
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233682] Dose of
Prexasertib
Cytotoxic therapi[INVESTIGATOR_882137]21days or5half-lives, whichever isshorter
Biologic agents that are large molecules including
immunotherapy28days
Investigational agents 28days.  If the agent has a long half-life (e.g. 
>2weeks) , then 3months or 5 half -lives 
(whichever is longer) should have passed 
Radiotherapy
Limited -field radiotherapy with palliative intent 14days
Other radiotherapy 28days
Major surgery, excluding biopsy 28days
[6]Have at least [ADDRESS_1233683] techniques by[CONTACT_882162](RECIST )version 1.1(Eisenhauer et al. 2009 ).
[7] Have given writteninformed consent priorto any study -specific procedures and agree 
and are able to follow the requirements of the protocol .
[
8] Are ofanacceptable age to provide informed consent according to the local
regul ationsandareatleast 18 years ofage.
[
9] H ave adequate organ funct ion, as defined below .  These values must be met during 
the baseline visit (prior to bi opsy )as well as predose Cycle 1 Day  1:
System Laboratory Value
Hematologic
ANC 1.5×109/L
Platelets 100×10 9/L
Hemoglobin 9g/dL
Note:  t ransfusions toincrease a patient’s hemoglobin level or initiation of erythropoietin or G -CSF 
therapy  tomeet enrollment criteria arenotallowed in the 14days preceding thefirstdose ofstudy drug.
If a patient receives transfusions, erythropoietin, or G -CSF therapy ≥[ADDRESS_1233684] bilirubin 1.5×ULN
ALT andAST 3×ULN OR
5×ULN iftheliver hastumor involvement
Renal
Serum creatinine OR
Measured creatinine clearance OR
Calculated creatinine clearance<1.5× ULN OR
40mL/min/1.73 m2
Albumin
Albumin >30 g/L OR
25-30 g/L and the value does not decrease across 
2 readings separated by ≥14 day s (without an 
intravenous albumin infusion)
I4D-MC-JTJN (b)Clinic al Protocol Page 28
LY2606368Abbreviations: ALT =alanine aminotransferase; ANC =absolute neutrophil count; AST =aspartate
amino transferase; G-CSF = granulocyte colony stimulating factor; ULN =upper limit ofnormal.
[10] Women of child -bearing potenti al parti cipat ing must agree to use one highly  effect ive 
(less than 1% failure rate) method of contraception or use a combination o f two 
effect ivemethods of contraception during treatment with study  drug and for at least
12weeks following the l ast dose of study  drug.
Note:  Unless not allowed by [CONTACT_24550], w
omen of child- bearing potenti al who 
are abst inent (if this is co mplete abst inence, as their preferred and usual lifestyle) or 
in a same sex relat ionship (as part of thei r pref erred and usual lifest yle) must agree to 
either rem ain abst inent or stay in a same sex relat ionship wit hout sexual relat ionships 
with males. Periodic abst inence (e.g., calendar, ovul ation, symptothermal, 
postovulat ion methods), declarat ion of abst inence just for the duration of a trial, and 
withdrawal  are not acceptabl e methods of contraception .
[
11] Women of child -bearing potenti al parti cipat ing must test negative for pregnancy  prior 
to init iation of treatment as indicated by  a negat ive pregnancy test at the screening 
visit (prior to bi opsy )andwithin 24 hours pri or of drug exposure.
[12] Cohorts 1 - 3:  Have documented testresults assessing alterations in the BRCA 1and
BRCA2 genes by [CONTACT_882163]. Results from 
either a blood or tissue based test are acceptable.
[13] Must beable and willing to undergo mandatory tumorbiopsy which will becollected
following determinat ion ofeligibilit y and before treatment (≤28 days beforeC1D1).   
Note that the biopsy may be co llected prior to the predose Cycle [ADDRESS_1233685] and labs. Tumor tissue obtained from a pri
or biopsymay be permitted for the
pretreatm entsample after discussio n and agreement between Lilly clinical research 
physician ( CRP ) /clinical research scient ist (CRS ) andinvestigator ifapatient has
not received any therapi[INVESTIGATOR_882138] .  The decision to use a tumortissue samplefrom a prior 
biopsy willbedocum ented in writing.
6.2. Exclusion Criteria
Patients will  be excluded from  the study  if they  meet anyof the fo llowing cri teria:
[14] Cohorts 1 - 3:Have previously received all o f the following agents at any  time in the 
platinum -resistant setting: gemcitabine, PEGylated liposo mal doxorubicin, and 
paclitaxel.  It is acceptable to have received 1or 2of these agents for plat inum -
resistant disease .
[15] Have n on-epi[INVESTIGATOR_882139]/non -epi[INVESTIGATOR_220] ( including malignant 
mixed Müllerian tumors ), ovarian tumors with low malignant potential (borderline 
tumors), endometrio id, clear cell , mucinous or l ow-grade serous carcinomas or not 
otherwi se specified (NOS) ovarian tumors .
I4D-MC-JTJN (b)Clinic al Protocol Page 29
LY2606368[16] H ave known central  nervous system  (CNS) malignancy o r metastasi s.  Patients wi th 
treated brain metastases that have been CNS recurrence -free for 1 y ear pri or to study  
treatm ent m ay be considered if approved by [CONTACT_92338]/CRS.
[17] Have prior m alignancies unless approved by  [CONTACT_92338]/CRS.  For i nstance, 
patients with carcino ma in situ of any origin and patients with prior malignancies 
who are in remissio n and whose likelihood of recurrence is very low, as judg ed by [CONTACT_133380]/CRS ,may beeligible for thi s study .
[
18] Are current ly enrolled in a clinical study involving an investigational product or any 
other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study .
[
19] H ave previously co mpleted or withdrawn fro m this study  or any  other study  
investigat ing prexasert ib or a CHK1 inhibitor or have shown hypersensit ivity to the 
study  drug or excipi[INVESTIGATOR_840] .
[
20] H ave a known serious medical condi tion(e.g., acti ve infection , increased risk of 
bleeding events ) that, in the opi[INVESTIGATOR_3078] n of the invest igator, woul d com promise the 
patient’s abilit y to adhere to the protocol or tol erate the study  treatm ent.
[
21] Have at least one of the following :
history  of abdo minal fistul aorgastrointestinal (GI)perforation
intra-abdo minal abscess within last 3months prior to the first dose of study  drug
aradiographically confirmed bowel  obstructi on(including sub -occlusive disease )
within [ADDRESS_1233686] dose of study  drug .
[
22] H ave a symptomat ic human immunodeficiency virus (HIV) infection or symptomat ic 
activated/reactivated hepat itis A, B, or C ( screening is not required ).
[
23] H ave a serious cardiac condit ion, such as:
symptom atic congestive heart failure or any  uncontroll ed cardi ac disease
[LOCATION_001] Heart Associat ion Class III/IV heart disease
unstable angina pectoris
symptom atic or poorly controlled cardiac arrhyt hmia
myocardial  infarct ion within the l ast 3 m onths
have a QT interval using Fridericia’s correction (QTcF) of >480msec on more 
than one electrocardiogram ( ECG )obtained during the baseline ( screening) period
family history  of long-QT syndrom e.
[24] Have a history  of prior radi otherapy  to the whole pelvis .
[
25] Have c hronic daily treatment with corticosteroids (dose >10 mg/day methyl -
predniso lone equivalent), excluding inhaled and topi [INVESTIGATOR_882140]
.
[26]Have known factors that may  increase the risk of infect ion while on study  drug 
treatm ent.  These m ay include, but are not limited to, an indwelling peritoneal 
catheter or open wounds.  Catheters for vascular access are permitted.
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233687] ions for thi s protocol .
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study (screen failure) m ay be 
rescreened .  Individuals may be rescreened a maximum  of 2 times.  The interval between 
rescreenings shoul d be ≥2weeks.  Each time rescreening is performed, the individual must sign a 
new informed consent form (ICF) and wil l be assigned a new ident ificat ion number.   Repeating 
of laboratory  tests during the screening period or repeating screening tests to complywith the 
protocol -designated screening period does not constitute rescreening .
I4D-MC-JTJN (b)Clinic al Protocol Page 31
LY26063687.Treatment s
7.1. Treatments Administered
Patients in allcohorts will receive 105 mg/m 2prexasertib as an approximately 60 (+10) minute 
intravenous (IV) infusio n on Day  1and [ADDRESS_1233688] igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the drug and planned duration of each individual’s 
treatm ent to the patient/study  site personnel/legal representative
verifying that instructions are fo llowed properly
maintaining accurate records of prexasertib dispensing and co llection
at the end of the study  returning all unused medication to Lilly, or its designee, 
unless Lilly  and si tes have agreed all  unused m edicati on is to be destroy ed by [CONTACT_39722], as all owed by [CONTACT_1769].
7.1.1. Packaging and Labelling
The drug product, prexasertib ( LY2606368 )for injection, is supplied for clinical trial use as a 
lyophilized, y ellow to whi te 
powder, in glass vials and is co mposed of prexasertib lactate 
monohydrate and the inact ive ingredients trehalose , polysorbate 80 and mannito l.  Clinical trial 
materi als will be labeled according to the country ’s regul atory  requi rements.
7.2. Method of Treatment Assignment
Upon ob taining informed consent, the site will register the patient via the interactive web 
response system (IWRS), whi ch is accessible 24 hours a day , to assi gn a pati ent number.  
Patients who m eet all cri teria for enrollment will be assigned to a cohort based on BRCA status, 
platinum resistant vs refractory, and /orlines of prior therapy .  The IWRS will be used to 
dispense study  drug to and/or track the allocation of each patient.
7.2.1. Selection and Timing of Doses
A cycle is defined as an interval of 28 days .
The actual  doses of study  treatment to be administered will be determined by [CONTACT_882164]’s BSA at the beginning of each cycle.  Although it i s accepta ble to recalculate more 
frequently, i f the pati ent’s weight does not fluctuate by  [CONTACT_726] 10% f rom the wei ght used to 
calculate the pri or cycle or fro m baseline , the BSA will not need to be recal culated.  A 10%
variance in the calculated total dose will be allowed for ease of dose administration.
A pat ient may cont inue to receive study  treatm entuntil she meets 1 or m ore of the specified 
reasons for discont inuatio n.
7.3. Blinding
This is an open -label study .
I4D-MC-JTJN (b)Clinic al Protocol Page 32
LY26063687.4. DoseModification
The fo llowing rul es shoul d guide dosing :
Before each dose :
Nonhematologic toxicit ies must resolve to Grade 0 or 1 or baseline, except AEs with no 
immediate medical consequence or those that can be controlled wit h adequate treatment 
(for example, pain, alopeci a, fatigue, nausea, vomiting, or diarrhea)
Neutropenia and anemia must resolve to Grade ≤2, and thrombocy topeni a to Grade ≤1,as 
show n inTable JTJN. 6.
Table JTJN. 6
. Hematologic Parameters Required Prior to Each Dose
Dose
Neutrophils ≥1000/mm 3
Platelets ≥75/mm 3
Hemoglobin ≥8 g/ dL
A delay  of a dose due to holiday, weekend, inclement weather, or other unforeseen 
circumstances will be permitted for a maximum o f 7 days and not co unted as a protocol 
deviat ion.
Initiation of  a dose may be delayed for a maximum of 14 days (28 day s from prior dose) 
to allow a pat ient sufficient time for recovery  from study  treatm ent related toxicit y(for 
example, a delay of 14 days fro m the planned Day  1 of the cycle) .  Note that i f the 
Day 15 dose cannot be administered within 7 days of the planned Day 15 (e.g. 21days 
from the prior dose (by  [CONTACT_2006]  22), i t shoul d be omi ttedand the next dose administered 
28days of the pri or dose as the start of a new cy cle. In addit ion, if there is a persist ent 
downward trend in the predose neutrophil/platelet counts a treatment delay may be 
considered.
Inexceptional circumstances, a longer delay is permitted upon agreement between the 
investigator and the Lilly CRP /CRS .Dosing delay of study drugs due to n on-study  drug 
related AEs m ay be permissible if deemed clinically  necessary  by [CONTACT_882165] n between the invest igator and the CRP /CRS .  The interval between 
prexasertib doses m ust not be l ess than 14 day s.  If a dose is delayed (for toxicit y or other 
circumstances), the next dose should be adjusted so that there is a ≥14- day interval.
Ifneeded, the cy cle length shoul d be extended to accommodate the delay . 
 Dose adjust ments and delays on ei ther Day  1 or 15 will be made based on the clinical 
assessment of hematologic and nonhematologic AEs as shown in Table JTJN. 7.  In addit ion, 
the dose can also be delayed or adjusted at the investigator ’sdiscret ion as clinically 
indicated. 
I4D-MC-JTJN (b)Clinic al Protocol Page 33
LY2606368Table JTJN. 7. Dose A djustments and Delays
ToxicityCTCAE
Grade ActionDose Adjustments and 
Considerations
Neutropenia Grade 3 or 
Grade 4Delay treatment until ≤Grade 2 (≥1000/mm3)
Recommend prophylactic 
G-CSFa
Thrombocytopenia Grade s2, 
3 or Grade 
4 Delay treatment until ≤Grade 1 (≥75/mm3) Investigator discretion
Anemia Grade 3 or 
Grade 4 Consider RBC transfusion or EPO (if consistent 
with institutional guidelines).  Delay treatment 
until ≤Grade 2 (≥8 g/dL)Investigator discretion
Febrile neutropenia
(without 
prophylactic 
G-CSF)Any 
GradeDelay treatment until afebrile and neutrophils
≤Grade 2 (≥1000/mm3)Investigator discretion  
Recommend prophylactic
G-CSFa
Febrile neutropenia
(with 
prophylactic 
G-CSF)Any 
GradeDelay treatment until afebrile and neutrophils
≤Grade 2 (≥1000/mm3)Reduce to next lower dose 
level unless there is 
documented agreement 
between investigator and 
CRP/CRS .
Allergic/
hypersensitivity 
reactionbGrade 1 or 
Grade 2 Administer treatment per institutional guidelines
for allergic/hypersensitivity reactions . Monitor 
closely  for any  worsening symptoms.  A reduced 
infusion rate can be used for subsequent 
infusions.Investigator discretion
≥Grade [ADDRESS_1233689] not receive any 
further treatment with prexasertib.
Other 
nonhematologic 
toxicitycGrade 2 Delay treatment until ≤Grade 1 or baselinedInvestigator discretion
Grade 3 or 
Grade 4Delay treatment until ≤Grade 1 or baseline Reduce to next lower dose 
level
Abbreviation s:  CRP = clinical research physician ;CRS = clinical research scientist; CTCAE = Common 
Terminology Criteria for Adverse Events version 4.0 ; G-CSF = granulocyte colon y stimulating factor ; 
RBC =red blood cells
aRefer to Section 7.7.
bPlease refer to the IB for the most recent guidance on allergic/hypersensitivity reactions
cExcept alopecia, fatigue, or toxicities that can be controlled with adequate treatment such as nausea, vomiting, 
diarrhea, or asymptomatic electrolyte disturbances .
dBaseline is considered prior to dosing on Cycle 1 Day 1 .
If a patient requires a dose reduction, prexasertib should be reduced as shown in Table JTJN. 8. 
After a dose reducti on, re
-escalat ion is acceptable.
I4D-MC-JTJN (b)Clinic al Protocol Page 34
LY2606368Table JTJN. 8. Prexasertib Dose Reductions
Reduction Dose
1stprexasertib dose reduction 80 mg/m 2
2ndprexasertib dose reduction 60 mg/ m2
3rdprexasertib dose reduction Discontinue from prexasertib
7.5. Preparation/Handling/Storage/Accountability
All prexasertib shoul d be refrigerated .
Prexasert ibwill be administered as an IV infusio n using a central or peripheral IV line and will 
be filtered through an in -line filter . Prexasert ib shoul d be handled according to standard 
procedures and precautions consistent wit h a cy totoxi c ant icancer drug.
The d osage strength of 67-mg prex asertib lactate mo nohydrate drug product will be used in 
Study  JTJN.  The vial will contain a slight excess to facilitate the withdrawal of the label ed
amount 67 mg/vial for use with an appropriate device, such as an infusio
n set.  Reconst ituting the 
vial contents wi th water for inject ion yields a clear yello w sol ution wi th a concentrati on of  
3.3mg/mL of prexasert ib.
For the most current detailed formulat ion informatio n and preparation instructions, refer to the 
IB and Pharmacy Binder.
7.6. Treatment Compliance
The study  medicat ion will be administered only at the invest igational sites by  [CONTACT_327788].  As a result, treatment compliance is ensured.
7.7. Concomitant Therapy
Except as noted, no other chemotherapy , immunotherapy, cancer -related horm one therapy , 
herbal drugs , or experimental  drugs will be permitted while the patients are on study  treatment.  
Patients on stabl e doses of bisphosphonates or RANK -L targeted agents (for example, 
denosum ab) are allowed to continue. These agents should not be init iated wi thin the 2 weeks 
prior to study  enrollment or at any  point while on the study .Replacement horm onal therapy or 
tamoxifen or arom atase inhibitors initiated before study  entry  will be all owed.
Radiotherapy  (including palliat iveradiotherapy ) will only be permitted if it is agreed upon by 
[CONTACT_882166]/CRS .  If the l esion that i s to be treated is a target lesio n, 
the lesio n will be censored at the time of treatment.   However, the patient may be eligible to 
remain on study  drug treatm ent provi ded there are other lesio ns that can be fo llowed for 
progression.  Treatment delays o f prexasertib may  be requi red if radi otherapy  is administered.
In addit ion, any disease progr ession requiring other forms of specific antitumor therapy will 
necessitate discontinuat ion from study  treatm ent.
Patients shoul d receive full supportive care during the trial.  Guidelines fro m ASCO (Smi th et al . 
2015) should be fo llowed for pati ents requi ring support wi th G-CSF.  Primary  or secondary  
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233690] an approximately 20% or higher risk for 
febrile neutropenia on the basis o f patient-, disease -, and treatment -related factors .  As outlined 
in the ASCO guidelines, the following factors may be relevant to the JTJN patient populat ion 
and should be considered when estimat ing the patient’s overall risk of febrile neutropenia:  Age 
≥65, advanced disease, previous chemotherapy  or radi ation therapy , poor nutri tional status , 
cardi ovascular disease, or m ultiple com orbid conditi ons.  It i s recommended that prophylactic 
short -acting G-CSF be init iated within 24-[ADDRESS_1233691]-nadir recovery (Crawford et al. 2010) .  It is recommended that long- acting G -CSFs, 
such as pegfilgrast im,be administered the day  after treatm ent(Crawford et al. 2017 ).  
Per NCCN 
guidelines, Phase 2 data support the use of pegfilgrastim in regimens wit h a 2 -week cy cle, with
uniform  consensus that this is appropri ate (Category  2A) ( Crawford et al. 2017 ).  .
Prophylactic ant ibiotics may be considered for use in patients who have experienced neutropenic 
fever or patients deemed at higher risk for neutropenic fever by [CONTACT_882167].  The treatm ent 
shoul d be consistent wi th ASCO gui delines (Flowers et al . 2013).
Erythropoi etin and packed RBC transfusion may be used according to ASCO guidelines 
(Rizzoet al. 2008) if clinically  indicated at any  time during the study . Patie nts who are stable on 
erythropoi etin for >1 m onth before study  entry may continue their treatment.
Ondays when prexasert ib is administered, patients should avoid taking mult iple ( >1) 
concomitant medicat ions that are known or suspected to cause prolonged QTc or Torsades de 
Pointes and, if possible, alternat ive agents should be considered. In addit ion, at the start of the 
study  and on days when prexasertib is administered, care should be taken to ensure that s erum 
electroly te levels are wi thin the normal range.
Strong P -gp and BRCP inhibitors (e.g.,amiodarone, carvedilo l, clarithromycin, dronedarone, 
itraconazo le, propafenone, quinidine, rano lazine, verapamil ,cyclosporine A, or eltrombopag )
shoul d be used wi th caution ,asprexasertib is a substrate of both P -gp and BCRP . 
7.8. Treatment after the End of the Study
Patients who are still on prexasertib at the time of study  com pletion may cont inue to receive 
prexasertib if they are experiencing clinical benefit  and no undue risks.  The continued access 
period will apply  to this study  only  if ≥[ADDRESS_1233692] igators when the cont inued access period begins.   Lilly may  allow 
patients to enroll in a “rollo ver” protocol to provide long -term continued access for patients 
enrolled in this study.
The continued access period will begin after study  com pletion and ends at End of Trial 
(Figure JTJN. 7.1). The patient ’s continued access to prexasertib will end when a cri terion for 
discontinuat ion is met (Section 8).  Conti nued access fo llow-up will begin the day  after the 
patient and the invest igator agree to discont inue prexasertib and lasts approximately  30 (±7) 
I4D-MC-JTJN (b)Clinic al Protocol Page 36
LY2606368days.  Follow- up procedures will be performed as shown in the Continue d Access Schedule of 
Activities Table JTJN. 3.
Figure JTJN. 7.1 . Continued access diagram.
Patients who are in short -term follow-up when the continued access period begins will cont inue 
in short -term follow-up unt il the 30
-dayshort -term fo llow-up visit is co mpleted.  Long -term 
follow-up does not apply.
Patients who ar e in long -term follow-up when the continued access period begins will be 
discontinued fro m long-term follow-up.

I4D-MC-JTJN (b)Clinic al Protocol Page 37
LY26063688.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
Patients will  be discont inued fro m study  treatm ent in the fo llowing circumstances :
the pati ent is enrolled in any  other clinical  study involving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this stud y
the pati ent becomes pregnant during the study
the pati ent is significant ly noncom pliant wi th study  procedures and/or treatment
disease progressi on
unacceptable toxicit y
the pati ent, f or any  reason, requi res treatm ent wi th another therapeuti c agent that 
has been dem onstrated to be effect ive for treatm ent of the study  indicat ion.  
Discontinuati on from prexasert ibwill occur prior to introduction of the new agent
the invest igator decides that the patient should be discontinued fro m prexasert ib
the pati ent re quests to be discont inued fro m prexasertib
the pati ent’s designee (legal representative ) reque sts that the patient be 
discontinued fromprexasert ib.
Patients who are di scont inued fromprexasert ibwill have fo llow-up procedures performed as 
shown in the Sch edule of Act ivities(Secti on 2).
8.1.1. Discontinuation of Inadvertently Enrolled Patients
If Lilly or the invest igator ident ifies a patient who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discussio n must occur between theLilly  CRP /CRS and the invest igator 
to determine if the patient may continue in the study.  If both agree it is medically appropriate to 
continue, the invest igator must obtain documented approval fro m the Lilly  CRP /CRS to allow 
the inadvert ently enro lled patient to continue in the study .Patients who are discont inuedfrom 
prexasertib will have follow
-up procedures performed as shown in the Schedule of Act ivities 
(Secti on 2).
8.2. Discontinuation from the Study
Patients will  be discont inued fro m the study  in the fo llowing circumstances:
the invest igator or Lilly, for any reason, but considering the rights, safet y and well -being 
of the pati ent(s) and in accordance with Internat ional Council  for Harm onizat ion
(
ICH) /Good Clinical Practice (GCP) Guidelines and local regulat ions, stops the study  or 
stops the patient’s participat ion in the study .
the pati ent becomes pregnant during the study .  See Secti on 9.2.1 regarding 
regul atory  reporting requi rements on fetal outcome.
I4D-MC-JTJN (b)Clinic al Protocol Page 38
LY2606368the invest igator decides that the patient should be discontinued fro m the study :
the pati ent requests to be discont inued fro mthe study :
the pati ent’s designee (legal representative ) requests that the pati ent be 
discontinued fro m the study . 
The study  will be di scontinued if Lilly judges it is necessary  for medical , safet y, regul atory , or 
other reasons consistent wi th applicable l aws, regulat ions, and GCP.  Prior to discont inuat ion, 
theEthical Review Board (ERB )(which approved the trial) will be notified according to local 
regul ation.
Patients who are discont inuedfromthe study will have follow-up procedures performed as 
shown in the Schedule of Act ivities(Secti on 2).
8.3. Lost to Follow -Up
A pat ient will be considered lost to fo llow
-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145].  Study  site personnel are expected to m ake 
diligent attempts to contact [CONTACT_57986] a sch eduled visit or who the site is 
otherwi se unable to follow -up.
Study  site personnel , or an independent third party , will attem pt to collect the survival status for 
all enrolled pat ients who are lost to fo llow
-up, including enrolle d pat ients who do not receive
prexasertib , within legal  and ethical  boundari es.  Public sources may  be searched for survival
status information.  If the patient ’s survival status is determined, the survival status will be 
docum ented, and the pati ent will n ot be consi dered l ost to f ollow -up.
Lilly personnel will not be invo lved in any attempts to collect survival status inform ation.
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233693] ivities(Secti on 2).
Com puted tom ography  (CT) scans, including spi[INVESTIGATOR_15143], are the preferred methods of 
measurement (CT scan thickness reco mmended t o be 5 mm); however, magnet ic resonance 
imaging (MRI )is also acceptable in certain situat ions, such as when body scans are indicated or 
if there is a concern about radiat ion exposure associated with CT.  Intravenous and oral contrast 
isrequi red unless m edically contraindicated.
The CT portion of a positron emission tomography (PET) -CT scan may be used as a method of 
response assessment if the site can document that the CT is o f ident ical diagnostic qualit y to a 
diagnos tic CT (wi th intravenous and oral contrast). A PET scan alone or as part of a PET -CT 
may be performed for addit ional analyses but cannot be used to assess response according to 
RECIST 1.1 (Eisenhauer et al . 2009) .
The m ethod of tum or ass essment used at baseline must be used consistently throughout the 
study .  Radi ologic scan of the thorax, abdomen, and pelvis is required
.Asan independent review 
of all or a subset of radiographic imaging scans may be conducted, copi[INVESTIGATOR_882141]  a coordinating vendor designated by  [CONTACT_11007].
See Secti on 10.3.[ADDRESS_1233694] igator should provi deadverse event (AE)verbat im terms and then the terms will be 
mapped by  [CONTACT_47551] i ts desi gnee to corresponding termino logy within the Medical Dict ionary for 
Regulatory  Activities (MedDRA )Lower Level term ( LLT)dictionary. The investigator will use 
Commo n Termino logy Criteria f orAdverse Events (CTCAE) version4.0to assign AE severit y 
grades.
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233695] igators are responsible for:
monitoring the safet y of patients in this study  and for al erting Lilly or its desi gnee 
to any  event that seem s unusual , even if this event may be considered an 
unant icipated benefit to the patient
the appropriate medical care of patients during the study
docum enting their review of each laboratory  safet y report
following ( through an appropri ate heal th care option) AEs that are serious or 
otherwi se medically  important, consi dered rel ated to study  treatm ent or the study , 
or that caused the patient to discont inue prexasert ibbefore com pleting the study.  
The patient should be fo llowed unt il the event resolves, stabilizes with appropriate 
diagnosti c evaluat ion, or is reasonably  explained.  Frequency of follow -
up 
evaluat ion is left to the discret ion of the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record via case report form ( CRF )/electr onic 
data entry  the occurrence and nature of each pat ient’s preexist ing condit ions, including clinically  
significant si gns and symptom s of the disease under treatment in the study .  In addi tion, study  
site personnel will record via CRF/electronic data entr yany change in the preexist ing condit ions 
and any  new condi tions as AEs.   Invest igators should record their assessment of the potential 
relatedness of each AE to study  procedure or study treatment via CRF/electronic data entry .
The invest igator will interpret and docum ent whether or not an AE hasa reasonable possibilit y 
of being related to study  treatm ent or a study  procedure, taking into account the disease, 
concomitant treatments ,or pathologies. A “reasonable possibilit y” means that there is a cause 
and effect relat ionship between the study  treatm ent and/or study  procedure and the AE.
Adverse event grading of toxicit ies related to estimated glo merular filtrat ion rate (GF R) shoul d 
be evaluated based on the Cockcroft -Gaul t method or m easured GFR ( Appendix 6 ).
Planned surgeries and nonsurgic al intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
Study  site personnel  must report any  dose m odificati ons or treatm ent discont inuat ions that result
from AEs to Lilly or its designee via CRF/electronic data entry , clarifying, if possible, the 
circumstances leading to the dose modificat ion or discontinuat ion of treatm ent.
9.2.1. Serious Adverse Events
An SAE is any  AE from this stud y that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
I4D-MC-JTJN (b)Clinic al Protocol Page 41
LY2606368congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or require hospi [INVESTIGATOR_110151], based upon 
appropriate medical judgment, they  may jeopardi ze the patient andmay require 
intervent ion to prevent one of the other outcomes listed in the definit ion above .
Although all AEs after signing the ICF are recorded by [CONTACT_29558]/electronic data entry , 
SAE reporting to Lilly begins after the patient has signed the ICF and has received prexasert ib.  
However, if an SAE occurs after signing the ICF, but prior to receiving prexasertib , itneeds to be 
reported ONLY if it is considered reasonably possibly related to study  procedure s.
Study site personnel  must notify Lilly or its designee of any SAE within 24 hours of investigator 
aware ness of the event via a Lilly -approved m ethod.  If alerts are i ssued via telephone, they are 
to be immediately followed wit h official notification on study -specific SAE forms.   This 24 -hour 
notification requirement refers to the init ial SAE informat ion and all fo llow-up SAE information.
Pregnancy (during m aternal exposure to prexasertib )does not m eet the definit ion of an AE but 
shoul d be reported.  However, to fulfill regulatory  requi rements any  pregnancy shoul d be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in pat ients once they  have 
discontinued and/or completed the study  (the patientsummary CRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a patient has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study participat ion, the invest igator m ust prom ptly notify Lilly .
Planned hospi [INVESTIGATOR_327765]’s medical history  at the time of enrollment should not be considered SAEs.  
Hospi[INVESTIGATOR_246638] a preci pi[INVESTIGATOR_4596] (for 
example, for the administration of study  treatm ent or other protocol -requi red procedure) shoul d 
not be considered SAEs.
Serious a dverse events, including death, caused by [CONTACT_882168] .
9.2.2. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected se rious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as rel ated to study  treatm ent or study  procedure.  
[LOCATION_002] 21 CFR 312.32 and Regul ation (EU) No 536/2014 and the associated detaile d 
guidances or nati onal regulatory  requi rements in parti cipat ing countries require the reporting of 
S[LOCATION_003]Rs.  Lilly has procedures that will be fo llowed for the recording and expedited reporting of 
S[LOCATION_003]Rs that are consistent with global regulat ions and asso ciated detailed guidances.
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233696] ivities (Section 2).
Results fromany clinical laboratory  test analyzed by  a central  laboratory  (refer to Appendix 2 )
will be provi ded toinvest igative sites by [CONTACT_223975] .
Refer to Section 9.2for details on the recording of AEs .
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by [CONTACT_82393].
[IP_ADDRESS]. Special Hepatic Safety Data Collection and Monitoring Criteria
Hepati c data shoul d be collected on the appropriate CRF forms inthe event that ≥1of the 
following condit ion
(s)aremet for the patient during the course of the study :
elevation of serum alanine aminotransferase (ALT ) ≥10 ×upper limit of normal (ULN )
without liver tum ors or m etastasi s: ALT ≥5×ULN and total bilirubin ≥ 2×ULN
with liver tum ors or m etastasi s: ALT ≥8×ULN and total bilirubin ≥ 2×ULN
discontinu
ation from study  treatmentdue to hepatic event or liver test abnormalit y
occurrence of a hepat ic event considered to be a nSAE .
Close hepat ic monitoring as outlined below shoul d be ini tiated if the fo llowing condi tions are
met b y a pat ient: 
elevated ALT 5×ULN and elevated total bilirubin 2×ULN or ALT 8×ULN 
for pati ents entering the study  with ALT >
3×ULN, m onitoring shoul d be tri ggered at 
ALT >2×baseline and el evated total  bilirubin 2×ULN .
Liver tests ( Appendix 5 ), including ALT, aspartate aminotransferase (AST), total bilirubin, direct 
bilirubin, gamma -glutamyl  transferase (GGT), and creatine phosphokinase (CPK), should be 
repeated within [ADDRESS_1233697] igator, b ased on the hepat ic monitoring tests ( Appendix 5 ) and in 
I4D-MC-JTJN (b)Clinic al Protocol Page 43
LY2606368consultation wit h the Lilly CRS/ CRP.  Moni toring of ALT, AST, and total bilirubin should 
continue until levels normalize or return to approximate baseline levels.
9.5. Pharmacokinetics
The PK samples will be collected as specified in the PKSampling Schedule ( Appendix 4 ). 
Sparse PK samples for prexasert ib will be collected over m ultiple cycles of therapy  to determine 
the plasma concentrati ons of prexasert ib.  The data fro m this study  will be pooled wi th other PK 
data in a planned populati on based PK meta -analysis .
At the visit s and t imes specified in the Study Schedule, venous blood samples will be collected 
to determine the plasma concentrations of prexasertib . A maximum o f [ADDRESS_1233698] ion and handling of blood sam ples will be provi ded by [CONTACT_103]. The actual date and time (24 -hour clock time) of each sampling will be recorded.
These samples will be analyzed at a laboratory  designated by  [CONTACT_882169] a validated 
liquid chro matography –mass spectrometry /mass spectrom etry (LC-MS/MS) m ethod. 
ThePK samples will be stored at a facilit y designated by  [CONTACT_456]. Bioanalyt ical samples 
collected to measure prexasertib concentrati ons will  be retained for a m aximum  of [ADDRESS_1233699] patient visit for the study , or 
for a shorter peri od if local regulations and/or ERBs/IRBs impose shorter time limits.   
This 
retenti on peri od enables use o f new techno logies, response to questio ns from regul atory  
agencies, and invest igation of variable response that may not be observed unt il later in the 
development of prexasertib or after prexasert ibbecom escommercially  available .
Molecular techno logies are expec ted to improve during the [ADDRESS_1233700] ing techno logies include whol e genom e and exo me 
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233701] ion, variabilit y of patient response (including safet y), and clinical 
outcom e.  Sam ple collect ion is incorporated into clinical studies to enable examinat ion of these 
questions through measurement of bio mole cules including deoxy ribonucleic acid ( DNA ), 
ribonucleic acid ( RNA ), proteins, lipi[INVESTIGATOR_805], and other cellular elements.   This study may analyze 
biomarkers relevant to prexasertib, the mechanism of action of prexasertib, the variable response 
to study  drugs, immune funct ion, tumor microenvironm ent, replication stress, angiogenesis, and 
pathways associated with high -grade serous ovari an, primary  peritoneal, or f allopi[INVESTIGATOR_76351].  
These samples m ay also be used to develop related research methods or to validate diagnostic 
tools or assays .
The collection of a pretreatment tumor biopsy  is requi red in Study  JTJN for exploratory  
correl ative bio marker research because archival tumor tissue obtained from biopsies collected 
years earlier might not accurately refle ct the m olecular alterati ons that m ay have occurred during 
the evo lution of the disease (Olson et al. 2011
). Both archived t issue and a pretreatment biopsy 
are collected in Study  JTJN so that change s in potent ial markers that may be related to sensit ivity 
to prexasertib can be assessed .
Testing to assess BRCA status will be completed at the Study  JTJN central laboratory on newly 
obtained pretreatm ent biopsies or archival tissuesaccepted in place of newly obtained 
pretreatm entbiops ies(See Secti on 9.8.1 ).  Thi s testing is in addit ion to the l ocal laboratory  
BRCA testing used to meet eli gibili ty and for cohort assi gnment.
It is possible that bi omarker data for patients in the study  havealready been generated from 
samples that were collected and analyzed prior to enro lling in this study .  This m ay include data 
generated fro m genet ic analyses.  If available, these data may be requested fro m medical records
for use in the research described in Sect ions9.7,9.8.[ADDRESS_1233702] ion of the fo llowing tumor tissue sample
sis required for all pat ients to parti cipate in 
thisstudy :
a newly  obtained bi opsy specimen collected fo llowing determinat ion of eligibilit y and 
before treatment ( ≤28 days before C1D1) (see Sectio n 6.1, Inclusio n Cri terion [13]).
I4D-MC-JTJN (b)Clinic al Protocol Page 45
LY2606368Note: atumortissue sample obtained fro m a prior biopsy may  be permi tted f or the 
pretreatm ent sam ple after discussio n and agreement between Lilly CRP / CRS and 
investigator if a patient has not received any therapi[INVESTIGATOR_882142] .  This will  be permitted only  if a 
formalin-fixed paraffin -embedded (FFPE) tissue block i s available (slides are not 
acceptable).
an archived tumor sam plecollected at any time prior to di scont inuat ion of last therap y for 
the disease , if available and not restricted by  [CONTACT_54019].  Archived samples should 
be sent wi thin 2weeks o f C1D1.  It will not be considered a protocol deviat ion if this 
timeframe is not met, unless there are mult iple occurrences at a single site.
Collect ion of the following tumor tissue sample(s) is optional for all pat ients participat ing in this 
study:
additional optional biopsy samples may be requested at addit ional study  time points, if 
warranted and agreed upon by  [CONTACT_133411].  If these addit ional samples are 
requested, they  will be used to further investigate bio markers that m ay help further 
characterize treatm ent response and resistance mechanisms , particularly in pat ients that 
have experienced clinical benefit fro m prexasert ib.
The s ponsor has a ri ght to retain a portion of the submitted tissue , and archival bloc ks will be 
returned to the study  site.  Slides and ti ssue samples collected on study  will not be returned .
Tumor tissue samples shoul d be obtained using an excisio nal or core needle (minimum 
18gauge) biopsy.  Cytological samples and fine-needl e aspi [INVESTIGATOR_882143].
Archival FFPE tumor tissue obtained fro m the primary  tumor or m etastati c site shoul dbe 
provi ded as a block or unstained slides.  Due diligence should be used to make sure that tumor 
sample (not a normal adjacent or a tum or margin sam ple) is provi ded.  The p athol ogy report
accompanying tissue may also be requested. The pathol ogy report must be coded with the 
patient number. Personal ident ifiers, including the patient’s name [CONTACT_133430], must be removed
from the insti tutional pathol ogy report prior to submissio n.
Samples will  be retained at a facilit y selected by  [CONTACT_82395] a m aximum  of 15years 
after the l ast pati ent vi sit ofthe study , or for a shorter period if lo cal regulat ions and/or 
ERBs/IRBs impose shorter time limits.   This retentio n peri od enables the use of new
techno logies, response to questions fro m regul atory  agencies, and invest igation of variable 
response that may not be observed unt il later in the developm ent of prexasertib or after 
prexasertib beco mes co mmercially available.
Techno logies are expected to improve during the [ADDRESS_1233703] ing approaches, including mutation profiling, copy  number 
variabilit y analysis, gene expressio n assays, mult iplex assays, and/or immunohistochemistry  may 
be perform ed on these ti ssue samples to assess potent ial associ ations between these bio markers 
and clinical outcomes .
I4D-MC-JTJN (b)Clinic al Protocol Page 46
LY26063689.8.2. Other Samples for Biomarker Research
The fo llowing samples for bio marker research will be collected according to the sampling 
schedule in Section2, where local regulat ions allo w:
whole blood 
plasma .
A maximum of [ADDRESS_1233704] patient visit for the study , or f or a shorter peri od if local regulat ions 
and/or ERBs/IRBs impose shorter time limit s.  This retention period enables use o f new 
techno logies, response to questions fro m regul atory  agencies, and invest igationof variable 
response that may not be observed unt il later in the development of prexasertib or after
prexasertib beco mes co mmercially available.   Techno logies are expected to improve during the 
15-year storage period and, therefore, cannot be specifically named.  Exist ing approaches, 
including mutation profiling, copy  number vari ability analysis, gene expressio n assays, and/or 
multiplex assays may be performed on these tissue samples to assess potential associat ions 
between these bio markers and clinical outcomes.
9.9. Health Economics
Health care resource use information related to the frequency of hospi[INVESTIGATOR_602], emergency 
departm ent (
ED)visits, and small bowel obstruction (SBO) will be co llected to support the 
safet y assessment of prexasert ib.  Simi larly, informat ion on the fo llowing concomitant 
medicat ions will also be collected:  granulocy te or m acrophage colony stimulatingfactor 
(G[M] -CSF), 
erythropoi esis st imulating agent s (ESAs ), transfusio ns (pl ateletsand RBC s), 
antibiotics, antifungals, and analgesics ( over-the-counter [ OTC ]and prescription).
9.10. Health Outcome Measures
Palliat ion and symptom control are central to the treatment of most patients with advanced 
ovari an cancer, given the limit ed opportunit y for cure.  Thepatient-reported outcome (PRO) 
assessments in this study  will focus on two fundamental  concepts :ovari an cancer -related 
symptoms and worst pain .  These 2focused dimensions are among the highest priorit y to 
advanced ovarian cancer pat ients, based on direct input fro m patients as well as gyneco logic 
oncol ogy specialists ( Jensen et al.2011 and Cella et al. 2003).
The impact of prexasertib on ovarian
-cancer related symptom s will be measured via the National 
Comprehensive Cancer Network – Funct ional Assessment of Cancer Therapy –Ovari an 
Symptom  Index -18 (NFOSI-18) ( Table JTJN. 9). This instrument consists of 18 questions that 
comprise 3domains: disease -related symptoms, treatment -related si de effects, and funct ional 
well-being. It is a 5 -level, Li kert scal ewith the following response opti ons: “not at all, ”
“a little 
bit,” “somewhat, ” “quite a bi t,”or “very much.”The recall period is 7 day s. It was d eveloped 
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233705] relevant symptoms experienced by  [CONTACT_1962] (Jensen et al . 2011 ).
The impact of prexasertib on worst pain will be evaluated via the Worst Pain Num eric Rat ing 
Scale (NRS) (Table JTJN. 9). The Worst Pain NRS was developed after similar principles seen 
within Effect of Cancer on Qualit y of Life (Cleeland 1991).   The Worst Pain NRS is a single -
item, subject -administered, 11 -point horizontal scale anchored at 0 and 10, with 0 represent ing 
“no pain” and 10 represent ing “pain as bad as you can imagine.” 
Table JTJN. 9
. Instrume nts Used to A ssess Patient -Reported Outcomes
Concept(s) of Interest Instrument Number of questions
Ovarian cancer -related symptoms NCCN -FACT -FOSI -[ADDRESS_1233706] Pain NRS 1
Abbreviations: NRS = numeric rating scale ; NFOSI -18 = National Comprehensive Cancer Network –Functional 
Assessment of Cancer Therapy -
Ovarian Symptom Index -18.
Both instruments will be administered electronically via a handheld device. Only p atients fluent 
in an available translat ion will co mplete the questionnaires . If a translation is not available, the 
patient is still permitted to enter the study; however, this scenario must first be communicated to 
the study  team .  
Data on OTC and prescription analgesic medications including dose, unit, frequency, and route 
of administration will be collec ted by [CONTACT_882170]; itwill 
be analyzed in conjunct ion with patient-reported data from the Worst P ain NRS.  Any changes 
compared to the pri or infusio n
will be recorded.  Pain medicat ion will be cl assified into 
medicat ion categori es, using the analgesic quant ification algorithm (Chung et al . 2014 ). 
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233707] ivity for each cohort. A cohort will be closed if the 
posteri or probabilit y of activit y is <20%. Subsequent interim analyses will be done to further 
evaluate the posterior probabilit y ofactivity after addi tional patients are enrolled toeach cohort. 
The study  will enroll up to approximately 180 patients in total. The sample size for each cohort 
will be dependent on the outcomes of the interim analyses.  As cohorts are halted, new eligible 
patients will  be allocated to the enrolling cohorts. As a result, the maximum sample size o f a 
single cohort is approximately  120 pati ents (e.g. ,if enrollment to all but one of the cohorts is 
stopped after the first interim analysis).  The posterior 
credible intervals of ORR when the 
observed ORR is in the range of 0-35% aresummarized in Table JTJN. 10. For illustrative 
purpose, the study  drug will  be considered act ive if ORR>25% and the uniform prior beta (1,1) is 
assumed in the Bayesian model.  With the minimum sample size of N=20 , the p osterior 
probabilit y of ORR exceeding 25% is <20% if the upper bound of 60% credible interval is 
<25%. With the m aximum sample size of N=120, the posterior probabilit y of ORR exceeding
25% i s >80% if the l ower bound of 60% credible interval is >25%.
Thestudy efficacy  may be monitored on a nongoing basis . The decisio n to close a cohort early 
may be made if result s suggest the posterior probabilit y of ORR exceeding the prespecified 
thresho ld of act ivityis well below 20% . For example, if the true response rate is 25%, the 
probabilit y of observing 0 response sout of 6patients i s 17.8% . Under the uniform priorbeta 
(1,1) , the posterior probabilit y thatORR is greater than 25% is only 13.3% . If the true response 
rate is 15% , the probabilit y of observing 0 response sout of 10 patients is 19.7%. Under the 
same pri or,the posteri or probabilit y thatORR i s greater than 15% is only 16.7%.
Patients who have been assigned to a cohort but not treated may be repl aced to ensure that a 
sufficient number of pat ientscan be treated for each interim analysis .
I4D-MC-JTJN (b)Clinic al Protocol Page 49
LY2606368Table JTJN. 10. Observed ORR and 60% Credible Interval
N=20 N=120
Number of 
RespondersObserved 
ORR60% 
Credible IntervalNumber of 
RespondersObserved 
ORR60% 
Credible Interval
0 0% 1.1 %-7.4 % 0 0% 0.2 %-1.3%
1 5% 3.9%-13.6% 6 5% 3.9%- 7.4%
2 10% 7.4% -19.3% 12 10% 8.3 %-12.9 %
3 15% 11.1%-24.7 % 18 15% 12.8%-18.3 %
4 20% 15.1%-29.9 % 24 20% 17.4%-23.5 %
5 25% 19.1%-35.0 % 30 25% 22.1-28.7 %
6 30% 23.3%-40.0 % 36 30% 26.8% -33.8 %
7 35% 27.6%-44.9 % 42 35% 31.6%-38.9 %
Abbreviations: ORR=o verall response rate.
10.2. Populations for Analyses
The fo llowing analysis sets will be defined for this study :
Intent -to-Treat (ITT) population: will include all enro lled pat ients(i.e.,patients have been 
assigned to a cohort) . The ITTpopulat ion will be used for all baseline ,efficacy and PRO
analyses.
Per-Protocol population : will include all treated patients who do not have any major protocol
violations that could potentially  affect the efficacy  concl usionsof the study . This populati on will  
be used for efficacy  and PRO sensi tivity analyses.
Safety population :  will include all enrolled patients who have received ≥1 dose of prexasertib , 
regardl ess of thei r eligibili ty for the study . The safety  populati onwill be used for all 
dosing/exposure, and safet yanalyses.
Pharmacokinetic population : will include all enrolled patients who have received ≥[ADDRESS_1233708] baseline and ≥1postbaseline evaluable PK sample.
Biomarker population : will include all enrolled patients from who m a valid assay  resul t has 
been obtained. 
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y ofLilly or its desi gnee .
The primary analysis will be conducted approximately [ADDRESS_1233709] responder ’s first 
response date orapproximately [ADDRESS_1233710].Addit ionalupdated analyse s of efficacy and safet y may be conducted at later times 
(approximately 6-12 months after the primary  analysis )if deemed appropriate by [CONTACT_456].
All CIswill be given at a 2 -sided 95%
level, unless otherwi se stated .
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a princi pal feature of the protocol.  Any other change to the data analysis 
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233711] ical analysis plan ( SAP)and the clinical study  report.  Addi tional expl oratory  
analyses o f the data will be conducted as deemed appropriate.
10.3.1. Efficacy Analyses
Overall response rate (ORR) is defined as the number of patients who achieve a best overall 
response of co mplete response (CR) or partial response (PR) divided by [CONTACT_882171] .  The ORR ,with corresponding 95% exact CI,will be summarized
for each cohort. The posterior estimates of ORR and posterior probab ility of ORR that is greater 
than the cutoff value will also be derived via a Bayesian model. See details in Sect ion 10.3.4 .
Disease control rate (DCR) is defined as the number of patients who achieve a best overall 
response of CR, PR or stable disease for ≥4 months divided by [CONTACT_882172].  The DCR, with corresponding 95% exact CI,will be summarized foreach 
cohort .
CA-125 response is defined as ≥50% reducti on in CA -[ADDRESS_1233712] be conf irmed and maintained for ≥[ADDRESS_1233713] a pretreatment sample that is ≥2 times the upper limit of the reference range 
and obtained within 2 weeks before starting the treatment. The response rate based on CA -125 
will be summarized for each cohort.
Progression -free survival (PFS) is defined as the time fro m the first dose until the first
occurrence of docum ented di sease progressi on per RECIST 1.1,or death from any cause in the 
absence ofprogressive disease .Patients known to be alive and wi thout disease progression will 
be censored at the time of the last adequate tumor assessment (a detailed PFS event/censoring 
scheme is provided in SAP).
Duration of response (DoR) is defined as the time fro m the date m easur ement cri teria for CR or 
PR (whichever is first recorded) are first met unt il the first date that disease is recurrent or 
objective progression is observed, per RECIST 1.1, or the date of death fro m any cause in the 
absence of objectively determined diseas e progressio n or recurrence.  The DoR will be censored 
according to the same rules as PFS.
Overall survival (OS) is defined as the time from the first dose until death fro m any cause.  If 
the pati ent is alive ,lost to fo llow-up or wi thdrawn fro m study at the time of data analysis , OS 
data will be censored on the last date the patient is known to be alive.  
For time -to-event variables, such as PFS, DoR and OS, the Kaplan -Meier m ethod (Kaplan and 
Meier 1958) will be used to estimate the curves, median t ime and 95% CI for each cohort.
10.3.2. Safety Analyses
All patients who receive ≥1 dose of prexasertib will be evaluated for safet y and toxicity.
The Medical Dictionary  for Regul atory  Activit ies (MedDRA®) Versi on 20.0 (or higher) will be 
used when reporting AEs by [CONTACT_133416].  The MedDRA LLT will be used in the treatment -
I4D-MC-JTJN (b)Clinic al Protocol Page 51
LY2606368emergent com putati on.  Adverse events will be summarized by [CONTACT_1196] (SOC) and 
by [CONTACT_882173]  (PT) wi thin SOC. CTCAE version 4.0 will be used 
to report AE severit y grades.
Safety analyses will include summaries of the fo llowing:
AEs, including severit y and possible rel ationship to study  drug
SAEs , including possible relationship to study  drug
AEs leading to d ose adjust ments
discontinuat ions from  study  treatm ent due to AEs or death
treatm ent emergent abnormal changes in laboratory  values
treatm ent emergent abnormal changes in vital signs and ECGs .
10.3.3. Other Analyses
[IP_ADDRESS]. Patient Disposition
A detailed descr iption o f patient di sposi tion will be provi ded, including a summary  of the 
number and percentage of patients entered into the study , enrolled in the study , and treated ,as 
well as number and percentage of patients completing the study (patients who receive ≥1dose of 
study  drug and have ≥[ADDRESS_1233714] -baseline tumor assessment) , or di scont inuing (overall and by [CONTACT_882174]).  A summary  of all important protocol deviat ions will be provided.
[IP_ADDRESS]. Patient Characteristics
Dem ographic data are collected and reported to demo nstrate that the study  populati on represents 
the target patient populat ion.
A summary of baseline patient and disease characteri stics, historical diagnoses, preexist ing 
condi tions, and prio r therapi[INVESTIGATOR_882144] . Other 
patient baseline characterist ics will be summarized by  [CONTACT_882175].
[IP_ADDRESS]. Treatment Compliance
Study  treatm ent will be adm inistered at the invest igator site; therefore, treatment compliance is 
assured.
[IP_ADDRESS]. Extent of Ex posure
The number of cycles received ,cumulative dose, duration of therapy, dose omissio ns, dose 
reducti ons, dose delays, and dose intensit y will be summarized for all treated patients by[CONTACT_9084].
[IP_ADDRESS]. Concomitant Therapy
A summary of prior and concomitant medications by [CONTACT_882176].
[IP_ADDRESS]. Post -Study -Treatment Therapy
The numbers and percentages of patients receiving post- study -treatm ent ant icancer therapi[INVESTIGATOR_882145]  (surgery , radi otherapy , or sy stemic therapy ), and by  [CONTACT_882177]/or name, overall and by [CONTACT_27939] .
I4D-MC-JTJN (b)Clinic al Protocol Page 52
LY260636810.3.3.7. Pharmacokinetic/ Biomarker Analyses
A descript ive summary (for example , end of infusion, minimum plasma concentration [Cmin], 
and accumulat ion rati o) of  the prexasertib PK data collected from all pat ients who receive ≥[ADDRESS_1233715] samples co llected for analysis of prexasert ib plasma concentration 
data will be provided across mult iple cycles o f treatm ent.  The observed PK data will a lso be 
compared wi th the current prexasert ib human populat ion PK model (fro m Study  JTJA) and 
included with the descript ive summary  in the final clinical study  report .
Mean populat ion PK param eters for prexasert ib in plasma (clearance, vo lumeof distribut ion, and 
half-life) and inter -individual PK variabilit y will also be computed for this study  using nonlinear 
mixed -effect modelling implemented in NONMEM in order to describe the dose -concentration 
relationship in the target populat ion.  Covar iate effects (such as age, BSA, prior therapi[INVESTIGATOR_014], 
hepat ic/renal funct ion, etc .) on the PK parameters of prexasertib will also be invest igated .
Addit ionalexploratory popul ation based PK/pharmacodynamic analyses using nonlinear mixed 
effect modeling implemen ted in NONMEM may be perform ed (if the data warrant) that include 
the re-estimation of prexasertib PK par ameters at the pat ient level to:
evaluate the potential relat ionship between PK and bio markers
evaluate the relationship between exposure and response in terms of safet y and 
efficacy  (e.g., neutropeni a, CA -125, change in tumor size, PFS, OS, etc.) .
The populat ion based PK and PK/pharmacodynamic analyses will be reported in separate 
standalo ne report s for this study .  The versio n of an y software used for the analyses will be 
docum ented, and the program will meet the Lilly requirements of software validat ion.  It is 
possible that other validated equivalent PK software programs may be used if appropriate, 
warranted, and approved by [CONTACT_882178] .
[IP_ADDRESS]. Biomarker Analyses
Summary  statistics for bi omarkers (e.g.,BRCA status based on the central lab) will be reported.  
The association between bio markers and clinical outcome swill be explored. Further ex ploratory  
analysis of bio markers may be conducted if deemed necessary and a sufficient number of 
patients who express the bio marker(s) are available.
[IP_ADDRESS]. Health Outcome/ Patient -Reported Outcomes
For each questionnaire , the com pliance rate by  [CONTACT_882179] (that is, patients still on 
study ).  Com pliance rates will be c alculated for each quest ionnaire. Reasons f or noncom pliance
will be collected only for assessments administered via the site -based device .
Home device : 
For the worst pain NRS, missed assessments will not be considered a protocol deviat ion 
provi ded that in a given cycle all of the fo llowing cri teria are met:
≥50% of the assessments are completed
4/[ADDRESS_1233716] dose of each cycle ,
starting prior to cycle 2 .
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233717].  
Site-based device:
The target compliance threshold /com pletion rate for the NFOSI -[ADDRESS_1233718] p ain NRS is 100% ;
every missed assessment will be considered a protocol  deviat ion.
Change from baseline for pre -specified concepts of interest (worst pain and ovarian cancer 
related symptom s)will be descriptively analyzed. Time to progression will be summarized for 
the pre-specified concepts of interest descriptively using the KM method .Data for cohorts that 
have stopped early  may not be analyzed. Exploratory  analyses may be conducted on other 
domains as well as individual items of the NFOSI -18. Data on analgesic consumpt ion will be
analyzed in conjunct ion with PRO data from the worst p ainNRS .The associat ion between PRO
measures and efficacy outcomes willbe evaluated .Further details will be defined in the SAP.
[IP_ADDRESS]. Healthcare Resource Utilization
Hospi[INVESTIGATOR_602], transfusio ns, EDvisits, SBO, and concomitant medicat ions during study  
treatm ent will be summarized by [CONTACT_9084] .
10.3.4. Interim Analyses
Interim analyses will be conducted regularly to evaluate closing enrollment early due to fut ility. 
For each cohort, the first futility interim analysis will be conducted after approximately 
[ADDRESS_1233719] been treated and completed ≥[ADDRESS_1233720] -
baseline tumor assessment. Although confirmation of response is not required to complete the 
interim analysis , the interim analysis may be potentially  delayed to ob tainconfirmat ion of 
response .The fut ility rule is based on the posterior probabilit y of activity via a Bayesian model. 
A cohort will be closed if the posterior probabilit y is less than the prespecified fut ility thresho ld 
(e.g.,20% probabilit y that 
ORR exceeds the prespecified thresho ld of activit y). Borrowing of 
inform ation across cohorts may  be allowed, and the strength of borrowing may depend on the 
similarit y among the cohorts. The pri or distributi on of response rate used in the model may be
derived fro m the ongoing NCI-sponsored Phase 2 Study  E001 ( [STUDY_ID_REMOVED]).   The fut ility 
rules for each cohort are described as fo llows(ORR of 25% and 15% are considered the 
thresho ld of activityfor Cohorts 1 –3 and 4, respectively ):
Cohorts 1 to 3 (plat inum -resistant): Pr (ORR>25%) <20%
Cohort 4 (platinum -refractory ):Pr (ORR>15%) <20% .
It is planned that enrollment can continue while interim analyses are conducted, but the sponsor 
may decide to pause the enro llment, if necessary.  For the cohorts that can continue after the 
evaluat ion of the app roximately first 20 patients , subsequent interim analyses will occur after 
approximately  every  20 addi tional pat ients.  The interval between interim analyses may be 
adjusted if deemed appropriate based on enro llment rates and available data . At each subsequent 
interim for each cohort , the posteri or probabilit y of response rate will be updated based on the 
available data and a higher fut ility thresho ldfor the posterior probabilit ymay be adopted if 
deem ed appropri ate by [CONTACT_456] .
I4D-MC-JTJN (b)Clinic al Protocol Page 54
LY2606368At each interim analysis , although the decisio n ofwhether to continue a cohort will be made 
primarily based on the futilit y rules, the totalit y of data (including safet y, efficacy, PK, and 
biomarker data ,if available )will also be reviewed and considered in the final deci sionmade by 
[CONTACT_212934].The decision will be co mmunicated to sites in writ ing if the sponsor determine sa 
cohort is to be closed. The evaluat ion of efficacy may be based on all treated patients with 
centrally  confirmed BRCA mutation status if available .  Other interim analyses may be conducted 
if deemed appropriate by  [CONTACT_456] .  Theinterim analyses may be co mbined if they are 
expected to occur within a similar timeframe ; interim analyses may also be combined with any  
prespecified safet y review or annual reporting ( such as an update to the IBor Development 
Safety Update Review , etc. ).
I4D-MC-JTJN (b)Clinic al Protocol Page 55
LY260636811.References
Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, 
Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. BRCA mutation 
frequency  and patterns of treatment response in BRCA mutation- positive women with ovarian 
cancer: a report fro m the Australian Ovarian Cancer Study  Group. J Clin Oncol . 
2012;30(21):2654 -2663.
Brooks K, Oakes V, Edwards B, Ranall M, Leo P, Pavey S, Pi[INVESTIGATOR_78005] A, Beamish H, 
Mukhopadhyay  P, Lambie D, Gabri elli B. A potent Chk1 inhibitor is selectively  cytotoxi c in 
melano mas with high levels of replicat ive stress. Oncogene . 2013;32(6):788 -796.
Burger RA, Brady  MF, Bookm an MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley 
HD, Fowl er J, Greer BE, Boente M, Birrer MJ, Liang SX; Gyneco logic Oncol ogy Group. 
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med . 
2011;365(26):[ADDRESS_1233721] important 
symptom  targets when treating advanced cancer? A survey  of provi ders in the Nat ional 
Com prehensive Cancer Network (NCCN) .Cancer Invest . 2003;21
(4):526-535.
Chung KC, Barlev A, Braun AH, Qian Y, Zagari M. Assessing analgesic use in pat ients with 
advanced cancer: development of a new scale --
the Analgesic Quantificat ion Algorithm. 
Pain Med. 2014;15(2) :225-232.
Cleeland C. Pain assessment in cancer. In: Osoba D, ed. Effect of 
cancer on qualit y of life. Boca 
Raton: CRC Press, Inc.; 1991:293 -
305.
Cockcroft DW, Gault M H. Prediction of creat inine clearance fro m serum  creat inine. Nephron . 
1976;16 (1):31-41.
Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, Diski n SJ, Attiyeh EF, 
Sennett R, Norris G, Laudenslager M, Wood AC, Mayes PA, Jagannathan J, Winter C, Mosse 
YP, Maris JM. RNAi screen of the protein kino me ident ifies checkpo int kinase 1 (CHK1) as a 
therapeuti c target in neuroblastoma. Proc Natl Acad Sci U S A. 2011;108(8):[ADDRESS_1233722] A, Rampal R, Roy  V, Rugo HS, Saad AA, Schwartzberg LS, Shayan i S, 
Talbott M, Vadhan -Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L. My eloid 
Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Onco logy. J Natl 
Compr Canc Netw . 2017;15(12):1520-1541.
Crawford J, Caserta C, Roila F; ESMO Guidelines Working Group. Hematopoiet ic growth 
factors: ESMO Clinical Practice Guidelines for the applicat ions. Ann Oncol . 2010;21 (Suppl 
5):v248 -v251. 
Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling 
network. Clin Cancer Res . 2010;16(2):376 -383.
Davis A, Tinker AV, Friedlander M. “Platinum resistant” ovarian cancer: what is it, who to treat 
and how to m easure benefit ? Gynecol Oncol . 2014;133(3):624 -
631.
I4D-MC-JTJN (b)Clinic al Protocol Page 56
LY2606368Dubeau L , Drapkin R . Coming into focus: the nonovarian ori gins of ovarian cancer. Ann Oncol . 
2013;24( Suppl 8):viii28 –viii35.
Eisenhauer EA, Therasse P, Bogaert sJ, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumours: revised RECIST guideline (versio n 1.1). 
Eur J Cancer . 2009;45(2) :228-247.
Etem admoghadam  D, Wei r BA, Au
-Yeung G, Alsop K, Mitchell G, George J; Australian 
Ovarian Cancer Study Group, Davis S, D’Andrea AD, Simpson K, H ahn WC, Bowtell DD. 
Synthetic let hality between CCNE1 amplificat ion and loss o f BRCA1. Proc Natl Acad Sci 
U S A . 2013;110(48):[ZIP_CODE] -[ZIP_CODE].
Flowers CR, Sei denfeld J, Bow EJ, Karten C, Gleason C, Hawley  DK, Kuderer NM, 
Langston AA, Marr KA, Ro lston KV, Ramse y SD. Antimicrobial prophylaxis and outpatient 
management of fever and neutropenia in adults treated for malignancy: American Societ y of 
Clinical Onco logy clinical  pract ice guideline. J Clin Oncol. 2013;31(6):794 -810.
Gore ME, Fry att I, Wiltshaw E, Dawson T. Treatment of relapsed carcino ma of the ovary  with 
cisplatin or carboplat in following init ial treatment with these co mpounds. Gynecol Oncol . 
1990;36(2):207 -211.
Hoskins PJ, O’Reilly  SE, Swenerton KD. The ‘failure free interval’ defines the likelihood of 
resistance to carboplat in in pat ients with advanced epi[INVESTIGATOR_882146]: relevance to therapy and new drug testing. Int J G ynecol Cancer . 
1991;1(5):205 -208.
Jensen SE, Rosenbloo m SK, Beaumo nt JL, Abernethy  A, Jacobsen PB, Sy rjala K, Cella D. 
Anew index o f priori ty symptom s in advanced ovarian cancer. Gynecol Oncol .
2011;120 (2):214-219.
Jones RM, Mortusewicz O, Afzal I, Lorvel lec M, Garcí a P, Helleday  T, Peterm ann E. Increased 
replicat ion initiation and conflicts with transcript ion underlie Cyclin E -induced replication 
stress. Oncogene . 2013;32(32):3744 -3753.
Kaplan EL, Meier P. Nonparametric estimat ion of inco mplete observat ions. J Amer Stat Assoc . 
1958;53 (282) :457-481.
Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, 
Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology  Group. Dose -dense 
paclitaxel once a week in co mbinat ion with carboplat in every 3 weeks for advanced ovarian 
cancer: a phase 3, open -label, randomised controlled trial. Lancet . 2009;374(9698):[ADDRESS_1233723] D, Dempsey  J, Bl osser W, Beckm ann R, Barda D, 
Marshall MS. LY2606368 causes replicati on catastrophe and ant itumor effects through CHK1-
dependent mechanisms. Mol Cancer Ther . 2015;14(9):2004- 2013.
Konstantinopoulos PA, Ceccaldi R, Shapi[INVESTIGATOR_76604], D ’Andrea AD. Homo logous recombination 
deficiency: explo iting the fundamental vulnerabilit yof ovarian cancer. Cancer Discov . 
2015;5(11):1137 -1154.
I4D-MC-JTJN (b)Clinic al Protocol Page 57
LY2606368Krajewska M, Fehrmann RS, Schoonen PM, Labib S, de Vries EG, Franke L, van Vugt MA. 
ATR inhibit ion preferent ially targets hom ologous recombinat ion-deficient tum or cells. 
Oncogene . 2015;34(26) :3474 -3481.
Kroeger PT Jr, Drapkin R. 
Pathogenesis and heterogeneit y of ovarian cancer. Curr Opin Obstet 
Gynecol . 2017;29(1):26 -34.
Lecona E, Fernández -Capetillo O. Replication stress and cancer: it takes two to tango. Exp Cell 
Res. 2014;329(1):26 -34.
Lee J, Karzai FH, Zimmer A, Annunziata CM, Lipkowitz S, Parker B, Houston N, Ekwede I, 
Kohn EC . A phase II study  of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; 
prexasertib mono mesylate monohydrate) in sporadic high -grade serous ovari an cancer 
(HGSOC) and germline BRCA mutati on-associ ated ovari an cancer (g BRCA m+ OvCa). Paper 
presented at: European Societ y for Medical Onco logy (ESMO) 2016 Congress; October 7 -11, 
2016; Copenhagen, Denmark.
Lin AB, McNeely SC, Beckmann RP. Achieving precisio n death with cell- cycle inhibitors that 
target DNA replicat ion and repair. Clin Cancer Res . 2017;23(13):3232- 3240. 
Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer . 2016;16(2):[ADDRESS_1233724] CJ, Ashworth A. Mechanisms o f resistance to therapi[INVESTIGATOR_882147] -mutant cancers. 
Nat Med . 2013;19(11):1381 -1388.
McNeely S, Beckman R, Bence Lin AK. CHEK again: revisit ing the development of CHK1 
inhibitors for cancer therapy . Pharmacol Ther . 2014;142(1):[ADDRESS_1233725] -of-care agents [a bstract]. 
Mol Cancer Ther . 2011;10( Suppl 11) :A108 .
Murai  J. Targeti ng DNA repair and replicat ion stress in the treatment of ovarian cancer. 
IntJClin Oncol . 2017;22(4) :619-628.
[NCCN] National Co mprehensive Cancer Network. NCCN guidelines. National Comprehensive 
Cancer Network web site. Available at:  
http://www.nccn.org/professio nals/physician_gls/f_guidelines.asp.  Accessed 
October 20,
2016.
Oken MM, Creech RH , Torm ey DC, Horton J , Davis TE, McFadden ET, Carbone PP. Toxi city 
and response criteria o f the Eastern Cooperative Oncology Group .Am J Clin Oncol . 
1982;5 (6):649-655.
Olson EM, Lin NU, Krop IE ,Winer EP. The ethical use of mandatory
 research biopsies.  Nat 
Rev Clin Oncol. 2011;8(10):620 –625. 
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233726] I, 
Bell-McGuinn K, Coleman RL, O ’Malley DM, Leary  A, Chen LM, Provencher D, Ma L, 
Brenton JD, Konecny  GE, Castro CM, Gi ordano H, Mal oney  L, Gobl e S, Lin KK, Sun J, 
Raponi M, Rolfe L, Kristel eit RS. Ant itumor activity  and safety  of the PARP inhibitor 
rucaparib in pat ients with high -grade ovari an carcinom a and a germline or somat ic BRCA1 or 
BRCA2 mutation: integrated analysis of data fro m Study  10 and ARIEL2. Gynecol Oncol . 
2017;147(2):267-275.
Ozols RF, Bundy  BN, Greer BE, Fowler JM, Clarke -Pearson D, Burger RA, Mannel RS, 
DeGeest K, Hartenbach EM, Baergen R; Gyneco logic Oncol ogy Group. Phase III trial of 
carbopl atin and paclitaxel co mpared with cisplat in and paclitaxel in pat ients with optimall y 
resected stage III ovarian cancer: a Gyneco logic Oncol ogy Group study . 
J Clin Oncol.
2003;21(17):3194 -3200.
Parm ar MK, Ledermann JA, Colo mbo N, du Bois A, Delalo ye JF, Kristensen GB, Wheeler S, 
Swart AM, Qian W, Torri V, Floriani I, Jay son G, Lam ont A, T ropé C; ICON and AGO 
Collaborators. Paclitaxel plus platinum -based chemotherapy  versus convent ional plat inum -
based chemotherapy  in wo men with relapsed ovarian cancer: the ICON4/AGO -OVAR -2.2 
trial. Lancet . 2003;361(9375):[ADDRESS_1233727] 
platinum response and surviv al in ovarian, fallopi[INVESTIGATOR_8916], and peritoneal carcino mas. 
Clin Cancer Res . 2014;20(3):764 -775.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade -Lauraine E, Kristensen G, Carey  MS, 
Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stäh le A, Collinson F, 
Essapen S, Gourley C, Lortholary  A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, 
QianW, Parmar MK, Oza AM; ICON7 Invest igators. A phase 3 trial of bevacizumab in 
ovari an cancer. N Engl J Med . 2011;365(26):2484-2496.
Rizzo P, Osi po C , Forem an K, Gol de T, Osborne B ,Miele L. Rati onal targeting of Notch 
signaling in cancer. Oncogene .2008;27(38):5124 -
5131. 
Rondinelli B, Gogola E, Yücel H, Duarte AA, van de Ven M, van der Sluijs R, 
Konstantino poulos PA, Jonkers J, Ceccaldi R, Rottenberg S, D’Andrea AD. 
EZH2 promotes 
degradation of stalled replication forks by [CONTACT_882180]81 through histone H3 
trimethylat ion. Nat Cell Biol. 2017;19(11):1371 -1378.
Rundle S, Bradbury  A, Drew Y, Curtin NJ. Targeting the ATR -CHK1 axis in cancer therapy . 
Cancers (Basel) . 2017;9(5): E41.
Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, 
Medi ola C, Coens C, Qian W, Parmar MK, Swart AM; M RC OV05; EORTC [ADDRESS_1233728] igators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 
[ZIP_CODE]): a randomised trial. Lancet . 2010;376(9747):1155 -1163.
I4D-MC-JTJN (b)Clinic al Protocol Page 59
LY2606368[SEER] Surveillance, Epi[INVESTIGATOR_145975], and End Resul ts Program , Nati onal Cancer Institut e. SEER 
fast stats: an interactive tool for access to SEER cancer statist ics. Surveillance, Epi[INVESTIGATOR_145975], 
and End Results (SEER) Program web site. Available at:  h ttp://seer.cancer.gov/index.ht ml. 
Accessed October 20, 2016.
Siegel RL, Miller KD, Jemal A. C ancer statistics, 2017. CA Cancer J Clin. 2017;67(1):[ADDRESS_1233729] J, Cross SJ, Goldberg JM, 
Khatcheressian JL, Leighl NB, Perkins CL, Somlo  G, Wade JL, Wozniak AJ, Armitage JO; 
American Societ y of Clinical  Oncol ogy. Reco mmendat ions for the use of WBC growth 
factors: American Societ y of Clinical  Oncol ogy clinical practice guideline update. 
JClin Oncol . 2015;33(28):3199-3212.
Soslow RA. Histol ogic subt ypes of ovarian carcinoma: an overview. Int J Gynecol Pathol . 
2008;27(2):161-174.
Vasey  PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay  A, 
Kaye SB; Scottish Gynaeco logical Cancer Trials Group. Phase III randomized trial of 
docetaxel -carbopl atin versus paclitaxel -carbopl atin as first -line c hemotherapy  for ovarian 
carcino ma. J Natl Cancer Inst . 2004;96(22):1682
-1691.
Zeng L, Beggs RR, Cooper TS, Weaver AN, Yang ES. Combining Chk1/2 inhibit ion with 
cetuximab and radiat ion enhances in vitro and in vivo cy totoxi city in head and neck squamous 
cell carcino ma. Mol Cancer Ther . 2017;16(4):591 -600.
I4D-MC-JTJN (b)Clinic al Protocol Page 60
LY2606368Appendix 1. Abbreviations and Definitions
Term Definition
AE Adverse event:  any untoward medical occurrence in a patient or clinical investigation 
patient administered a pharmaceutical product and that does not necessarily have a 
causal relationship with this treatment.  An adverse event can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal 
(investigat ional) product, w hether or not related to the medicinal (investigational) 
product.
ALT alanine aminotransferase
ANC absolute neutrophil count
ASCO American Society of Clinical Oncology
AST aspartate aminotransferase
BRCA negative refers to patients with BRCA test results negative for deleterious or suspected 
deleterious BRCA mutations .
BRCA positive refers to patients with BRCA test results positive for deleterious or suspected 
deleterious BRCA mutations
BUN blood urea nitrogen
BSA body surface area
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
Cmin minimum plasma concentration
CNS central nervous system
collection database a computer database where clinical study data are entered and validated
CPK creatine phosphokinase
CR complete response
CRF case report form
CRP clinical research physician:  Individual responsible for the medical conduct of the 
study.  Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician, or other medical officer.
CRS clinical research scientist
CT computed tomography
CTCAE Common Terminology Criteria for Adverse Events
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233730]-in -human dosing
GCP good clinical practice
G[M}-CSF Granulocy teor macrophage colon y stimulating factor
GFR glomerular filtration rate
GGT gamma -glutamyl transferase
GI gastrointestinal
Highly effective method 
of contraceptionContraception methods that have <1% failure rate.  Examples include oral 
contraceptives implanted contraceptives or intrauterine devices
HGSOC high-grade serous ovarian cancer
HIV human immunodeficiency virus
HRR homologous recombination repair
IB Investigator’s Brochure
IC50 half-maximal inhibitory concentration
ICF informed consent form
I4D-MC-JTJN (b)Clinic al Protocol Page 62
LY2606368Term Definition
ICH International Council for Harmonization (formerly the International Conference on 
Harmonization )
interim analysis an analysis of clinical study data conducted before the final reporting database is 
created/locked
investigational product A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical study, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthoriz ed indication, or marketed products used to 
gain further information about the authorized form.
IRB institutional review board
ITT intent-to-treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_882181] e basis of the intention to treat a patient (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of th at group irrespective of their compliance to 
the planned course of treatment.
IWRS interactive Web response system
LC-MS/MS liquid chromatography –mass spectrometry/mass spectrometry
LLT MedDRA Lower Level Term
MedDRA Medical Dictionary for Regulatory Activities
MRI magnetic resonance imaging
NCCN Natio nal Comprehensive Cancer Network
NFOSI -18 Natio nal Comprehensive Cancer Network –Functional Assessment of Cancer Therapy -
Ovarian Symptom Index -
18
NRS numeric rating scale
ORR objective response rate
OS overall survival
OTC over-the-counter
PARP Poly (ADP -ribose) poly merase
PD progressive disease
PET positron emission tomography
PFS progression -free survival
PK pharmacokinetic(s)
PLD PEGy lated liposomal doxorubicin
PR partial response
I4D-MC-JTJN (b)Clinic al Protocol Page 63
LY2606368Term Definition
PS performance status
PT MedDRA Preferred Term
QTc corrected QT interval
QTcF QT interval using Fridericia’s correction
randomize the process of assigning patients to an experimental group on a random basis
RBC red blood cell
RECIST Response Evaluation Criteria in Solid Tumors
reporting database A point -in-time copy of the collection database.  The final reporting database is used to 
produce the analyses and output reports for interim or final analyses of data.
rescreen to screen a patient who was prev iously  declared a screen failure for the same study
SAE serious adverse event
SAP statistical analysis plan
SBO small bowel obstruction
SD stable disease
screen The act of determining if an individual meets minimum requirements to become part 
of a pool of potential candidates for participation in a clinical study.
screen failure patient who does not meet one or more criteria required for participation in a study
SOC MedDRA System Organ Class
study completion Study completion occurs after the clin ical trial database is locked and the final analysis 
of the primary and secondary endpoints have been performed., as determined by [CONTACT_11007].
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
ULN upper limit of normal
WBC white blood cell
I4D-MC-JTJN (b)Clinic al Protocol Page 64
LY2606368Appendix 2. Clinical Laboratory  Tests
Clinical Laboratory Tests
Hematology a,c Clinical Chemistry a,b
Leukocytes (WBC) Serum Concentrations of:
Neutrophils c Alanine aminotransferase (ALT)
Lymphocy tes Albumin
Monocytes Alkaline phosphatase
Eosinophils Aspartate aminotransferase (AST)
Basophils Bilirubin, direct
Erythrocy tes (RBC) Bilirubin, total
Hemoglobin (HGB) Blood urea nitrogen (BUN) or blood urea
Hematocrit (HCT) Calcium
Platelets (PLT) Creatinine
Glucose (random )
Urinalysis c Potassium
Blood Protein
Glucose Sodium
CA-[ADDRESS_1233731]
Urine leukocyte esterasee
Abbreviations:  CRF = case report form ; RBC = red blood cells; WBC = w hite blood cells.
aTreatment and enrollment decisions will be based on local laboratory results.
Note:  Neutrophils reported by [CONTACT_882182]. When a manual differential is needed to report the neutrophils, the segmented and band forms should be 
added together and recorded on the CRF, unless the CRF specifically provides an entry field for bands.
bCentral laboratory.  In addition, local labs may be collected at investigator ’sdiscretion.
cLocal or investigator -designated laboratory.
dFor female patients of childbearing potential.
eUrine microscopy may be used in place of the urine leukocyte esterase assessment to test for the presence of 
WBC
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233732] igator is responsible for:
ensuring that the patient understands the nature of the study , the potential risks 
andbenefits of participat ing in the study , and that the pat ient’s participat ion is 
voluntary
ensuring that informed consent is given by [CONTACT_6904].  This includes obtaining 
the appropriate signatures and dates on the informed consent form ( ICF) prior to 
the perform ance of any  study procedures and prior to the administration of 
prexasertib
provi ding a copy  of the signed ICF(s) to the patient and retaining a copy  of the 
signed ICF in the site file
answering any quest ions the pati ent m ay have throughout the st udy and sharing in 
a timely manner any  new informat ion that m ay be rel evant to the pati ent’s 
willingness to continue the pati ent’s participat ion in the study .
Ethical Review
Docum entati on of  ERBs/IRBs approval  of the protocol and the ICF must be provi ded to Lilly
before the study  may begin at the invest igative site(s).  Lilly or its representatives must approve 
the ICF, including any changes made by  [CONTACT_41429]/IRBs, before it is used at the invest igative 
site(s).  All  ICFs must be com pliant wi th the ICH gui deline on good clinical pract ice (GCP ).
The study  site’s ERBs/IRBs should be provided with the following:
protocol , protocol  amendments, and relevant protocol  addenda, and the current IB
and updates during the course of the study
ICFs
other relevant docum ents (for example, curri cula vi taeadvertisements) .
Regulatory Considerati ons
This study  will be conducted in accordance wit hthe protocol and with :
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council for International Organization s of 
Medical Sciences (CIOMS) International Ethical Guidelines 
applicable ICH GCP Guidelines
applicable laws and regulations .
Some obligat ions of Lilly may  be assigned to a thi rd-party  organizat ion.
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233733] igators in this clinical trial.
Protocol Signatures
Lilly ’sresponsible medical officer will approve the protocol, confirming that, to the best of his
or her knowledge, the protocol accurately describes the planned design and conduct of the study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Final Report Signature
[CONTACT_92397] , indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
The invest igator with the most enrolled pat ients will serve as the clinical study  report 
coordinat ing investigator.  If this invest igator is unable to fulfill this funct ion, another 
investigator will be chosen by  [CONTACT_92375].
The Lilly responsible medical officer and statist ician will approve the final clinical study  report
for this study , confi rming that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as app ropriate
sponsor start -up training to instruct investigators and study coordinators.  This sessio n 
will give instruction on the protocol, complet ion ofcase report forms (CRFs ), and study  
procedures.
make periodic visit s to the study  site
be available for consultation and stay in contact [CONTACT_47556], 
telephone, and/or fax
review/ evaluate CRF data using standard computer edits to detect errors in data collect ion
conduct a qualit y review of the database .
In addit ion, Lilly or its rep resentatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47551] i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice be fore 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide Lilly, 
applicable regulatory  agencies, and applica ble ERBs/IRBs wit h direct access to ori ginal  source 
docum ents.
I4D-MC-JTJN (b)Clinic al Protocol Page 67
LY2606368Data Capture System
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  [CONTACT_848456] -provi dedelectroni c data capture system.
Electronic pat ient-reported outcome (ePRO) measures (for example, a rating scale) or other data 
reported direct ly by [CONTACT_102] (for example, daily  dosing schedule, event diary ) are entered into 
an ePRO instrument at the time that the informat ion is obtained.  In these instances where there 
is no pri or wri tten or electronic source data at the site, the ePRO instrument record will serve as 
the source.
If ePRO records are stored at a third -party  site, investi gator si tes will have continuous access to 
the source documents during the study  and will  receive an archival copy  at the end of the study  
for retenti on.
Any data for which the ePRO instrument record will serve to collect source data will be 
ident ified and document ed by  [CONTACT_92366]’s study  file.
Case report form data collected via InForm, the clinical trial datab ase, will  be encoded by  a 
third-party  organi zation and stored el ectroni cally in the third- party  organi zation’s database 
system . Data managed by a central  vendor, such as l aboratory  test data, will be stored 
electroni cally in the central vendor’s database syst em.  Validated data will be transferred from 
these systems to the Lilly data warehouse, using standard Lilly file transfer processes.
Any da ta for whi ch the paper docum entati on provided by  [CONTACT_92365] i dentified and documented by  [CONTACT_92366]’s study  file.  Paper 
docum entati on provi ded by  [CONTACT_81146], for example, a daily dosing s chedule, or an 
event di ary.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly or its designee, the invest igator, or the 
ERB/IRB of the study  site judges i t necessary for medical, safet y, regul atory , or other reasons 
consistent with applicable laws, regulat ions, and GCP.
Discontin uation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233734] infusio n times.  
The PKblood sam ples shoul d not be withdrawn from the same IV site as the drug infusio n.
Predose (that i s, pri or to infusio nof prexasert ib)sample shoul d be taken as close as possible to 
the start of the infusio n (<2 hours and ideally <10 minutes prior to start ), and the exact clock 
reading should be recorded.  Postdose (that is, end of infusio n) PK samples should be drawn 
immediately  after end of infusio n (range = after end of infusio n +15minutes), and e xact cl ock 
reading should be recorded. Although every  effort to shoul d be m ade to ob tain the samples in 
the timeframes described above and noted below in the table , PK samples taken outside the 
specified windows will not be considered a protocol deviation . Similarly, a missed PK sample
(i.e., not collected at all or collected improperly) will not be considered a protocol deviat ion.
Prexasertib Pharmacokinetic Sampling Sch edule
Sample Series Cycle Day Prexasertib PK Sampling Timesa
1 1 1 End of prexasertib infusion (+15min)b
2 1 1 1-2 hours following end of prexasertib infusionb
3 2 1 Prior to start of prexasertib infusion 
4 2 1 End of prexasertib infusion (+15min)b
5 2 1 1-2hours following end of prexasertib infusionb
6 4 1 End of prexasertib infusion (+15min)b
7 4 1 1-2 hours following end of prexasertib infusionb
8 6 1 End of prexasertib infusion (+15min)b
9 6 1 1-2 hours following end of prexasertib infusionb
Abbreviations: min=minute; PK = pharmacokinetic.
aThe sampling schedule is relative to the prexasertib infusion times as noted in the table.  The actual timing of the 
samples may be adjusted at the discretion of Lilly and the investigators as PKdata become available .  
bPK samples that are collected after the start of the infusion will need to be drawn from a clean site, unless an 
adequately  flushed vascular access catheter is the only option (record in CRF if the case) .
I4D-MC-JTJN (b)Clinic al Protocol Page 69
LY2606368Appendix 5. Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly clinical research physician.
Hepatic M onitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin (HGB)
Hematocrit (HCT) Hepatic Coagulation a
Erythrocy tes (RBC) Prothrombin time (PT)
Leukocytes (WBC) Prothrombin time, INR
Neutrophils b
Lymphocy tes Hepatic Serologies a,c
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets (PLT) Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
Alanine aminotransferase (ALT) Recommended Autoimmune Serology a
Aspartate aminotransferase (AST) Anti- nuclear antibody
Gamma -glutamyl transferase (GGT) Anti-smooth muscle antibody
Creatine phosphokinase (CPK) Anti- actin antibody
Abbreviations:  CRF =case report form; IgG =immunoglobulin G; IgM =immunoglobulin M; INR =international 
normalized ratio; RBC =red blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated laboratory.
bNeutrophils reported by [CONTACT_133423]. Whenever a manual differential is needed to report the neutrophils, the segmented and band forms should 
be added together and recorded on the CRF, unless the CRF specifically provides an entry field for bands.
cReflex/confirmation dependent on regulatory requirements and/or testing availability.
I4D-MC-JTJN (b)Clinic al Protocol Page 70
LY2606368Appendix 6. Creatinine C learance Formula
Note:   This formula is to be used for calculat ing creatinine clearance (CrCl) fro m 
local laboratory results only.
Cockcroft -Gaul t predi ction of creatinine clearance fro m serum  creatinine (1976)
For serum creat inine concent ration in mg/dL :
CrCl =
(mL/min)(140 – agea) (wt) 0.85 (if female) , or1.0 (if male)
72serum creatinine (mg/dL )
For serum creat inine concentration in µmol/L:
CrCl =
(mL/min)(140 – age a) (wt) 0.85 (if female) , or1.0 (if male)
0.81serum creatinine (mol/L)
aAge in y ears, weight (wt) in kilograms.
Source:  Cockcroft and Gault 1976 .
I4D-MC-JTJN (b)Clinic al Protocol Page 71
LY2606368Appendix 7. Protocol A mendment I4D-MC-JTJN (b) 
Summary
APhase 2Study ofPrexasertib inPlatinum -Resistant or
Refractory Recurrent Ovarian Cancer
Overview
Protocol  I4D-MC-JTJN (APhase 2Study ofPrexasertib inPlatinum -Resistant or Refractory
Recurrent Ovarian Cancer )has been amended.  The new protocol is indicated by  [CONTACT_61504] ( b) 
and will be used to conduct the study  in place of any  preceding versio n of the protocol .
The overall changes and rationale for the changes made to this protocol are as fo llows:
Secti on 2 Table JTJN.1. Schedule of Inclusio n and Baseline Assessments: clarified that 
Cohort 4 does not need local BRCA resul ts
Secti on [ADDRESS_1233735] -Study Trea tment Foll ow-Up Schedul e of Activities: differentiated fo llow-
up intervals for patients who have discont inued without progression versus with 
progression
Secti on 6.1 Incl usion Cri teria: inclusio n [3] cl arifies what i s considered as a line of 
therapy
Secti on 7.4 Table JTJN.7: included Grade 2 for consideration in thrombocytopenia; 
specified when treatment should be delayed for anemia
Secti on 10.2: included definit ion for per -protocol populat ion
Secti on 10.3: m odified when to conduct primary analysis and additional updated analyses 
of efficacy and safet y,based on a recommendat ion fro m the FDA
Secti on [IP_ADDRESS] Extent of Exposure: clarified definit ion with addi tional criteria
Secti on 10.3.4 In terim Analyses: defined thresh old of activity for each cohort
I4D-MC-JTJN (b)Clinic al Protocol Page 72
LY2606368Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Addit ions have been identified by  [CONTACT_58002] .
The numbering system used for inclusio n and exclusion criteria provides a unique number for 
each cri terion and all ows for efficiency in data collection.
In case an amendment to the protocol adds a criterion, that criterion will receive the next 
available number, regardless of whether it is an inclusio n or excl usion cri terion.
I4D-MC-JTJN (b)Clinic al Protocol Page 73
LY2606368Table JTJN. 11. Schedul e of Inclusion and Baseline Assessments
Procedure 
Category Procedure Comments
Study Entry/ 
Enrollment…
Cohorts 1 -3: 
Confirm availability 
of local BRCA resultXData from a blood or tissue based test are acceptable (i.e. ,either germline 
or somatic tests are acceptable).  The test may have occurred prior to 
consent. If both somatic and germline status are known, the somatic 
status should be used for cohort assignment. Patients in Cohort [ADDRESS_1233736]-Study-Treatment Follow -UpSchedule of Activities
…
aPeriod begins the day after the decision that the patient will discontinue study treatment is made and lasts 
approximately [ADDRESS_1233737] to follow -up. 
6.1  Inclusion Criteria
[3] …
Note for Cohorts 1 and 2:  Each line of therapy  is preceded by  [CONTACT_882183] (initial therapy is considered the firs t line) .  
Switch of an agent within the same drug class (for example, cisplat in to 
carbopl atin) within a regimen to manage toxicit y does not define the start of a 
new line of therapy .  Similarly, maintenance therapy  (continuat ion maintenance or 
switch m aintenance) will  not be considered a new line of treatment.   Neither 
adjuvant therapy  nor horm onal therapy are considered lines of therapy .Horm onal 
therapy  is not considered a line of therapy .  All adjuvant therapy  shoul d be 
considered as a line of therapy . 
I4D-MC-JTJN (b)Clinic al Protocol Page 74
LY2606368Table JTJN. 12. Dose A djustments and Delays
ToxicityCTCAE
Grade ActionDose Adjustments and 
Considerations
…
Thrombocytopenia Grade s 2,
3 or Grade 
4 Delay treatment until ≤Grade 1 (≥75/mm3) Investigator discretion
Anemia Grade 3 or 
Grade 4 Consider RBC transfusion or EPO (if consistent 
with institutional guidelines).  Treatment may 
proceed or be delayed at the discretion of the 
investigator. Delay treatment until ≤Grade 2 (≥8 
g/dL)Investigator discretion
…
10.2. Populations for Analyses
The fo llowing analysis sets will be defined for this study :
…
Per-Protocol population : will include all treated patients who do not have any major protocol
violations that could potent ially affect the efficacy  concl usions of the study .  Thi s populati on will  
be used for efficacy  and PRO sensi tivity analyses.
10.3. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y of Lilly or i ts desi gnee.
The primary  analysis of the primary  endpoint of ORR will be performed when all enrolled 
patients have co mpleted ≥2 months of fo llow-up and/or investigator -assessed best response 
assessments have been co mpleted for all pat ients.  All secondary endpo ints will be evaluated at 
this time. will be conducted approximately [ADDRESS_1233738] responder’s first response date 
or approximately  [ADDRESS_1233739].
Addit ional updated analyses o f efficacy and safet y may be conducted at later times 
(approximately 10-[ADDRESS_1233740] patient is enro lledthe primary  analysis ) if deemed 
appropriate by  [CONTACT_456].
[IP_ADDRESS] Extent of Exposure
The number of cycle s received, cumulative dose, duration of therapy, dose omissio ns, dose 
reducti ons, dose delays, and dose intensit y will be summarized for all treated patients by[CONTACT_9084].
I4D-MC-JTJN (b)Clinic al Protocol Page [ADDRESS_1233741] been treated and completed ≥[ADDRESS_1233742] -
baseline tum or assessment.  Al though confirmation of response is not required to complete the 
interim analysis, the interim analysis may be potentially  delayed to ob tain confirmat ion of 
response. The fut ility rule is based on the posterior probabilit y of activity via a Bayesian model.  
A cohort will be closed if the posterior probabilit y is less than the prespecified fut ility thresho ld 
(e.g., 20% probabilit y thatORR exceeds the prespecified thresho ld of activit y).  Borrowing of 
inform ation across cohorts may  be allowed, and the strength of borrowing may depend on the 
similarit y among the cohorts.  The pri or distributi on of  response rate used in the model will be
may be derived fro m the ongoing NCI-sponsored Phase 2 Study  E001 ( [STUDY_ID_REMOVED] ).  The 
futilit y rulesfor each cohort are described as fo llows (ORR of 25% and 15% are considered the 
thresho ld of act ivity for Cohorts 1 –3 and 4, respectively) :
Cohorts 1 to 3 (plat inum -resistant):  Pr (ORR>25%) <20%
Cohort 4 (pl atinum -refractory ):  Pr (ORR>15%) <20%.
It isplanned that enrollment can continue while interim analyses are conducted, but the sponsor 
may decide to pause the enro llment, if necessary.  For the cohorts that can continue after the 
evaluat ion of the approximately first 20 patients, subsequent interim analyses will occur after 
approximately  every  20 addi tional pat ients.  The interval between interim analyses may be 
adjusted if deemed appropriate based on enrollment rates and available data.  At each subsequent 
interim for each cohort, the posteri or pro babilit y of response rate will be updated based on the 
available data and a higher fut ility thresho ldfor the posterior probabilit ymay be adopted if 
deem ed appropri ate by [CONTACT_456] (e.g., 40% probabilit y ORR exceeds the prespecified 
thresho ld of act ivity).
Leo Document ID = dff0e9fc-5663-410a-a5b6-e796458f5426
Approver:
Approval Date & Time: 17-Sep-2018 14:05:08 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]